{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:38:06Z","timestamp":1770331086734,"version":"3.49.0"},"reference-count":244,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12265-025-10649-4","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T10:37:17Z","timestamp":1750847837000},"page":"1734-1770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Small Interfering RNA (siRNA) for Cardiorenal Disease: Mechanistic Insights from Preclinical and Clinical Studies"],"prefix":"10.1007","volume":"18","author":[{"given":"Sukriti","family":"Wadehra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amritpal","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"6292","key":"10649_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1126\/SCIENCE.AAD8709\/SUPPL_FILE\/AAD8709-SULLENGER-SM.PDF","volume":"352","author":"BA Sullenger","year":"2016","unstructured":"Sullenger BA, Nair S. From the RNAworld to the clinic. Science. 2016;352(6292):1417\u201320. https:\/\/doi.org\/10.1126\/SCIENCE.AAD8709\/SUPPL_FILE\/AAD8709-SULLENGER-SM.PDF.","journal-title":"Science"},{"key":"10649_CR2","doi-asserted-by":"publisher","DOI":"10.20935\/ACADMOLBIOGEN7329\/PDF","author":"DA Musa","year":"2024","unstructured":"Musa DA, Raji MO, Sikiru AB, Aremu KH, Aigboeghian EA. Promising RNA-based therapies for viral infections, genetic disorders and cancer. Acad Mol Biol Genomics. 2024. https:\/\/doi.org\/10.20935\/ACADMOLBIOGEN7329\/PDF.","journal-title":"Acad Mol Biol Genomics"},{"issue":"1","key":"10649_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMCIBR1613559\/SUPPL_FILE\/NEJMCIBR1613559_DISCLOSURES.PDF","volume":"376","author":"AA Levin","year":"2017","unstructured":"Levin AA. Targeting therapeutic oligonucleotides. N Engl J Med. 2017;376(1):86\u20138. https:\/\/doi.org\/10.1056\/NEJMCIBR1613559\/SUPPL_FILE\/NEJMCIBR1613559_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"10649_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/FBIOE.2021.628137\/XML\/NLM","volume":"9","author":"TR Damase","year":"2021","unstructured":"Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 2021;9: 628137. https:\/\/doi.org\/10.3389\/FBIOE.2021.628137\/XML\/NLM.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"10649_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/NAT.2018.29001.DOW","volume":"28","author":"SF Dowdy","year":"2018","unstructured":"Dowdy SF, Levy M. RNA therapeutics (Almost) comes of age: targeting, delivery and endosomal escape. Nucleic Acid Ther. 2018;28(3):107\u20138. https:\/\/doi.org\/10.1089\/NAT.2018.29001.DOW.","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10649_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-023-02147-Z\/TABLES\/2","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology. 2023;21(1):1\u201315. https:\/\/doi.org\/10.1186\/S12951-023-02147-Z\/TABLES\/2.","journal-title":"J Nanobiotechnology"},{"key":"10649_CR7","doi-asserted-by":"publisher","unstructured":"Le\u00f3n-Rom\u00e1n J, Azancot MA, Marouco C, Patricio-Liebana M, Zamora JI, Ramos Terrades N, \u2026 Soler MJ. A new era in the management of cardiorenal syndrome: the importance of cardiorenal units. CardioRenal Med. 2025;15(1):174-183. https:\/\/doi.org\/10.1159\/000543294\/4327825\/000543294.PDF","DOI":"10.1159\/000543294\/4327825\/000543294.PDF"},{"issue":"6","key":"10649_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/J.PCAD.2016.12.003","volume":"59","author":"KD Boudoulas","year":"2017","unstructured":"Boudoulas KD, Triposkiadis F, Parissis J, Butler J, Boudoulas H. The cardio-renal Interrelationship. Prog Cardiovasc Dis. 2017;59(6):636\u201348. https:\/\/doi.org\/10.1016\/J.PCAD.2016.12.003.","journal-title":"Prog Cardiovasc Dis"},{"key":"10649_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2021.693099\/XML\/NLM","volume":"12","author":"KN Pandey","year":"2021","unstructured":"Pandey KN. Molecular signaling mechanisms and function of natriuretic peptide receptor-a in the pathophysiology of cardiovascular homeostasis. Front Physiol. 2021;12: 693099. https:\/\/doi.org\/10.3389\/FPHYS.2021.693099\/XML\/NLM.","journal-title":"Front Physiol"},{"issue":"20","key":"10649_CR10","doi-asserted-by":"publisher","first-page":"27694","DOI":"10.1161\/JAHA.122.027694\/ASSET\/9DE5D3EC-65CA-40A3-80A7-BE3DAA14474C\/ASSETS\/GRAPHIC\/JAH37883-FIG-0001.PNG","volume":"11","author":"P Ranasinghe","year":"2022","unstructured":"Ranasinghe P, Addison ML, Webb DJ. Small Interfering RNA therapeutics in hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen-targeting small interfering RNA. J Am Heart Assoc. 2022;11(20):27694. https:\/\/doi.org\/10.1161\/JAHA.122.027694\/ASSET\/9DE5D3EC-65CA-40A3-80A7-BE3DAA14474C\/ASSETS\/GRAPHIC\/JAH37883-FIG-0001.PNG.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10649_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/JPM15010003","volume":"15","author":"A da Silva Menezes Junior","year":"2024","unstructured":"da Silva Menezes Junior A, Nogueira THM, de Lima KBA, de Oliveira HL, Botelho SM. Exploratory studies on RNAi-based therapies targeting angiotensinogen in hypertension: scoping review. J Personalized Med. 2024;15(1):3. https:\/\/doi.org\/10.3390\/JPM15010003.","journal-title":"J Personalized Med"},{"issue":"11","key":"10649_CR12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430\/ASSET\/1A476386-B846-40A5-9EF5-4387A520AA0B\/ASSETS\/GRAPHIC\/HYPERTENSIONAHA.122.19430.FIG03.JPG","volume":"80","author":"ML Addison","year":"2023","unstructured":"Addison ML, Ranasinghe P, Webb DJ. Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics. Hypertension. 2023;80(11):2243\u201354. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19430\/ASSET\/1A476386-B846-40A5-9EF5-4387A520AA0B\/ASSETS\/GRAPHIC\/HYPERTENSIONAHA.122.19430.FIG03.JPG.","journal-title":"Hypertension"},{"issue":"12","key":"10649_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000534217","volume":"147","author":"K Doi","year":"2023","unstructured":"Doi K, Matsuura R. Sympathetic nerve activation in acute kidney injury and cardiorenal syndrome. Nephron. 2023;147(12):717\u201320. https:\/\/doi.org\/10.1159\/000534217.","journal-title":"Nephron"},{"issue":"9","key":"10649_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/ANTIOX13091126","volume":"13","author":"CR Tirapelli","year":"2024","unstructured":"Tirapelli CR, Padovan JC. Oxidative stress in cardiorenal system. Antioxidants. 2024;13(9):1126. https:\/\/doi.org\/10.3390\/ANTIOX13091126.","journal-title":"Antioxidants"},{"issue":"3","key":"10649_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/S40620-017-0425-7\/METRICS","volume":"31","author":"GM Virz\u00ec","year":"2018","unstructured":"Virz\u00ec GM, Clementi A, Brocca A, de Cal M, Ronco C. Epigenetics: a potential key mechanism involved in the pathogenesis of cardiorenal syndromes. J Nephrol. 2018;31(3):333\u201341. https:\/\/doi.org\/10.1007\/S40620-017-0425-7\/METRICS.","journal-title":"J Nephrol"},{"key":"10649_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/978-94-007-4525-4_27","volume":"61","author":"MK Shanmugam","year":"2013","unstructured":"Shanmugam MK, Sethi G. Role of epigenetics in inflammation-associated diseases. Subcell Biochem. 2013;61:627\u201357. https:\/\/doi.org\/10.1007\/978-94-007-4525-4_27.","journal-title":"Subcell Biochem"},{"issue":"1","key":"10649_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0003-2697(75)90563-1","volume":"69","author":"OW van Assendelft","year":"1975","unstructured":"van Assendelft OW, Zijlstra WG. Extinction coefficients for use in equations for the spectrophotometric analysis of haemoglobin mixtures. Anal Biochem. 1975;69(1):43\u20138. https:\/\/doi.org\/10.1016\/0003-2697(75)90563-1.","journal-title":"Anal Biochem"},{"issue":"2","key":"10649_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/s0021-9258(17)33888-7","volume":"251","author":"WA Koontz","year":"1976","unstructured":"Koontz WA, Shiman R. Beef kidney 3 hydroxyanthranilic acid oxygenase. Purification, characterization, and analysis of the assay. J Biol Chem. 1976;251(2):368\u201377. https:\/\/doi.org\/10.1016\/s0021-9258(17)33888-7.","journal-title":"J Biol Chem"},{"issue":"18","key":"10649_CR19","doi-asserted-by":"publisher","first-page":"17176","DOI":"10.1161\/JAHA.120.017176\/ASSET\/52D07737-B5BE-4830-B419-378FC02346E8\/ASSETS\/GRAPHIC\/JAH35489-FIG-0006.PNG","volume":"9","author":"H Su","year":"2020","unstructured":"Su H, Zeng H, He X, Zhu SH, Chen JX. Histone acetyltransferase p300 inhibitor improves coronary flow reserve in sirt3 (Sirtuin 3) knockout mice. J Am Heart Assoc. 2020;9(18):17176. https:\/\/doi.org\/10.1161\/JAHA.120.017176\/ASSET\/52D07737-B5BE-4830-B419-378FC02346E8\/ASSETS\/GRAPHIC\/JAH35489-FIG-0006.PNG.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10649_CR20","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/ANTIOX10091356\/S1","volume":"10","author":"AG Lazar","year":"2021","unstructured":"Lazar AG, Vlad ML, Manea A, Simionescu M, Manea SA. Activated histone acetyltransferase p300\/CBP-related signalling pathways mediate up-regulation of NADPH oxidase, inflammation, and fibrosis in diabetic kidney. Antioxidants. 2021;10(9):1356. https:\/\/doi.org\/10.3390\/ANTIOX10091356\/S1.","journal-title":"Antioxidants"},{"issue":"4","key":"10649_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000492602","volume":"8","author":"GM Virz\u00ec","year":"2018","unstructured":"Virz\u00ec GM, Breglia A, Brocca A, De Cal M, Bolin C, Vescovo G, Ronco C. Levels of proinflammatory cytokines, oxidative stress, and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1. Cardiorenal Med. 2018;8(4):321\u201331. https:\/\/doi.org\/10.1159\/000492602.","journal-title":"Cardiorenal Med"},{"issue":"7","key":"10649_CR22","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/CELLS10071824","volume":"10","author":"B Delgado-valero","year":"2021","unstructured":"Delgado-valero B, Cachofeiro V, Mart\u00ednez-mart\u00ednez E. Fibrosis, the bad actor in cardiorenal syndromes: mechanisms involved. Cells. 2021;10(7):1824. https:\/\/doi.org\/10.3390\/CELLS10071824.","journal-title":"Cells"},{"key":"10649_CR23","doi-asserted-by":"publisher","unstructured":"Chen X, Yu C, Hou X, Li J, Li T, Qiu A, \u2026 Zhuang S. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-b and EGFR signaling pathways in obstructive nephropathy. Am J Physiol-Ren Physiol. 2020;319(6):F1003\u2013F1014. https:\/\/doi.org\/10.1152\/AJPRENAL.00261.2020\/ASSET\/IMAGES\/LARGE\/AJ-AFLU200034F010.JPEG","DOI":"10.1152\/AJPRENAL.00261.2020\/ASSET\/IMAGES\/LARGE\/AJ-AFLU200034F010.JPEG"},{"key":"10649_CR24","doi-asserted-by":"publisher","unstructured":"Aufhauser DD, Hernandez P, Concors SJ, O\u2019Brien C, Wang Z, Murken DR, \u2026 Levine MH. HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia\/reperfusion injury. Sci Rep. 2021;11(1):1-13. https:\/\/doi.org\/10.1038\/S41598-021-88242-3;SUBJMETA=154,1585,2144,309,4,4022,631,692;KWRD=ACUTE+KIDNEY+INJURY,DRUG+DISCOVERY+AND+DEVELOPMENT","DOI":"10.1038\/S41598-021-88242-3;SUBJMETA=154,1585,2144,309,4,4022,631,692;KWRD=ACUTE+KIDNEY+INJURY,DRUG+DISCOVERY+AND+DEVELOPMENT"},{"key":"10649_CR25","doi-asserted-by":"publisher","first-page":"1405569","DOI":"10.3389\/FPHYS.2024.1405569\/BIBTEX","volume":"15","author":"J Lu","year":"2024","unstructured":"Lu J, Qian S, Sun Z. Targeting histone deacetylase in cardiac diseases. Front Physiol. 2024;15:1405569. https:\/\/doi.org\/10.3389\/FPHYS.2024.1405569\/BIBTEX.","journal-title":"Front Physiol"},{"key":"10649_CR26","unstructured":"HDAC2 histone deacetylase 2 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved May 31, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=3066"},{"key":"10649_CR27","unstructured":"HDAC6 histone deacetylase 6 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved May 31, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=10013"},{"issue":"5","key":"10649_CR28","doi-asserted-by":"publisher","first-page":"F578","DOI":"10.1152\/AJPRENAL.00091.2023\/ASSET\/IMAGES\/LARGE\/AJPRENAL.00091.2023_F001.JPEG","volume":"325","author":"P Kumar","year":"2023","unstructured":"Kumar P, Brooks HL. Sex-specific epigenetic programming in renal fibrosis and inflammation. Am J Physiol-Ren Physiol. 2023;325(5):F578\u201394. https:\/\/doi.org\/10.1152\/AJPRENAL.00091.2023\/ASSET\/IMAGES\/LARGE\/AJPRENAL.00091.2023_F001.JPEG.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"10649_CR29","doi-asserted-by":"publisher","first-page":"1238706","DOI":"10.3389\/FPHAR.2023.1238706\/XML\/NLM","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu Z, Yang J, Du M, Xin W. Functioning and mechanisms of PTMs in renal diseases. Front Pharmacol. 2023;14:1238706. https:\/\/doi.org\/10.3389\/FPHAR.2023.1238706\/XML\/NLM.","journal-title":"Front Pharmacol"},{"issue":"9","key":"10649_CR30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/J.CJCA.2019.04.002","volume":"35","author":"H Yogasundaram","year":"2019","unstructured":"Yogasundaram H, Chappell MC, Braam B, Oudit GY. Cardiorenal syndrome and heart failure\u2014challenges and opportunities. Can J Cardiol. 2019;35(9):1208\u201319. https:\/\/doi.org\/10.1016\/J.CJCA.2019.04.002.","journal-title":"Can J Cardiol"},{"key":"10649_CR31","doi-asserted-by":"publisher","unstructured":"Rondeaux J, Groussard D, Renet S, Tardif V, Dumesnil A, Chu A, \u2026 Fraineau S. Ezh2 emerges as an epigenetic checkpoint regulator during monocyte differentiation limiting cardiac dysfunction post-MI. Nat Commun. 2023;14(1):1-15. https:\/\/doi.org\/10.1038\/s41467-023-40186-0","DOI":"10.1038\/s41467-023-40186-0"},{"issue":"5","key":"10649_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/GENES13050796","volume":"13","author":"F Liu","year":"2022","unstructured":"Liu F, Chen J, Li Z, Meng X. Recent advances in epigenetics of age-related kidney diseases. Genes. 2022;13(5):796. https:\/\/doi.org\/10.3390\/GENES13050796.","journal-title":"Genes"},{"key":"10649_CR33","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.2147\/DDDT.S376673;JOURNAL:JOURNAL:DDDT20","volume":"16","author":"YB Zhao","year":"2022","unstructured":"Zhao YB, Wei W, Lin XX, Chai YF, Jin H. The role of histone H3 methylation in acute kidney injury. Drug Des Dev Ther. 2022;16:2453\u201361. https:\/\/doi.org\/10.2147\/DDDT.S376673;JOURNAL:JOURNAL:DDDT20.","journal-title":"Drug Des Dev Ther"},{"key":"10649_CR34","doi-asserted-by":"publisher","unstructured":"Prabhakaran R, Thamarai R, Sivasamy S, Dhandayuthapani S, Batra J, Kamaraj C, \u2026 Mallik S. Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy. Epigenetics Chromatin 2024;17(1):1\u201326. https:\/\/doi.org\/10.1186\/S13072-024-00554-6","DOI":"10.1186\/S13072-024-00554-6"},{"issue":"1","key":"10649_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/J.MOLCEL.2021.11.026\/ASSET\/354A8B76-5492-4069-80A9-1C98FD1460EA\/MAIN.ASSETS\/GR3.JPG","volume":"82","author":"HO Iwakawa","year":"2022","unstructured":"Iwakawa HO, Tomari Y. Life of RISC: formation, action, and degradation of RNA-induced silencing complex. Mol Cell. 2022;82(1):30\u201343. https:\/\/doi.org\/10.1016\/J.MOLCEL.2021.11.026\/ASSET\/354A8B76-5492-4069-80A9-1C98FD1460EA\/MAIN.ASSETS\/GR3.JPG.","journal-title":"Mol Cell"},{"issue":"11","key":"10649_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.5061\/DRYAD.Z612JM69B","volume":"20","author":"EJ Duff","year":"1975","unstructured":"Duff EJ. An infrared and X-ray diffractometric study of the incorporation of fluoride into hydroxyapatite under conditions of the cyclic variation of pH. Arch Oral Biol. 1975;20(11):763\u20139. https:\/\/doi.org\/10.5061\/DRYAD.Z612JM69B.","journal-title":"Arch Oral Biol"},{"key":"10649_CR37","unstructured":"DNMT1 DNA methyltransferase 1 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved May 31, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=1786"},{"issue":"10","key":"10649_CR38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/PH17101353","volume":"17","author":"S Komal","year":"2024","unstructured":"Komal S, Gao Y, Wang ZM, Yu QW, Wang P, Zhang LR, Han SN. Epigenetic regulation in myocardial fibroblasts and its impact on cardiovascular diseases. Pharmaceuticals. 2024;17(10):1353. https:\/\/doi.org\/10.3390\/PH17101353.","journal-title":"Pharmaceuticals"},{"key":"10649_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.PHARMTHERA.2018.11.003","volume":"196","author":"S Xu","year":"2019","unstructured":"Xu S, Kamato D, Little PJ, Nakagawa S, Pelisek J, Jin ZG. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. Pharmacol Ther. 2019;196:15\u201343. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2018.11.003.","journal-title":"Pharmacol Ther"},{"key":"10649_CR40","unstructured":"Dipuo Dephney Motshwari B, Matsha Cindy George TE. Small non-coding RNA profiles in chronic kidney disease in the general population and high-risk sub-groups (with hypertension and\/or diabetes mellitus) in a South African community-based cohort. 2022; Retrieved from https:\/\/etd.cput.ac.za\/handle\/20.500.11838\/3822"},{"issue":"4","key":"10649_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/J.NCRNA.2023.08.009","volume":"8","author":"P Sun","year":"2023","unstructured":"Sun P, Wang J, Ilyasova T, Shumadalova A, Agaverdiev M, Wang C. The function of miRNAs in the process of kidney development. Non-Coding RNA Res. 2023;8(4):593\u2013601. https:\/\/doi.org\/10.1016\/J.NCRNA.2023.08.009.","journal-title":"Non-Coding RNA Res."},{"key":"10649_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2021.707461\/XML\/NLM","volume":"8","author":"X Xu","year":"2021","unstructured":"Xu X, Hong P, Wang Z, Tang Z, Li K. MicroRNAs in Transforming growth factor-beta signaling pathway associated with fibrosis involving different systems of the human body. Front Mol Biosci. 2021;8: 707461. https:\/\/doi.org\/10.3389\/FMOLB.2021.707461\/XML\/NLM.","journal-title":"Front Mol Biosci"},{"issue":"AUG","key":"10649_CR43","doi-asserted-by":"publisher","first-page":"371516","DOI":"10.3389\/FPHAR.2018.00903\/XML\/NLM","volume":"9","author":"N Li","year":"2018","unstructured":"Li N, Zhou H, Tang Q. miR-133: a suppressor of cardiac remodeling? Front Pharmacol. 2018;9(AUG):371516. https:\/\/doi.org\/10.3389\/FPHAR.2018.00903\/XML\/NLM.","journal-title":"Front Pharmacol"},{"key":"10649_CR44","doi-asserted-by":"publisher","unstructured":"Fan X, Gao Y, Zhang X, Lughmani HY, Kennedy DJ, Haller ST, \u2026 Tian J. A strategic expression method of miR-29b and its anti-fibrotic effect based on RNA-sequencing analysis. PLoS One. 2020;15(12):e0244065. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0244065","DOI":"10.1371\/JOURNAL.PONE.0244065"},{"key":"10649_CR45","doi-asserted-by":"publisher","first-page":"1447953","DOI":"10.3389\/FMOLB.2024.1447953\/XML\/NLM","volume":"11","author":"P Ubanako","year":"2024","unstructured":"Ubanako P, Mirza S, Ruff P, Penny C. Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges. Front Mol Biosci. 2024;11:1447953. https:\/\/doi.org\/10.3389\/FMOLB.2024.1447953\/XML\/NLM.","journal-title":"Front Mol Biosci"},{"key":"10649_CR46","doi-asserted-by":"publisher","first-page":"1423045","DOI":"10.3389\/FPHAR.2024.1423045\/XML\/NLM","volume":"15","author":"X Xing","year":"2024","unstructured":"Xing X, Rodeo SA. Emerging roles of non-coding RNAs in fibroblast to myofibroblast transition and fibrotic diseases. Front Pharmacol. 2024;15:1423045. https:\/\/doi.org\/10.3389\/FPHAR.2024.1423045\/XML\/NLM.","journal-title":"Front Pharmacol"},{"key":"10649_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2020.101607","volume":"36","author":"T Carbonell","year":"2020","unstructured":"Carbonell T, Gomes AV. MicroRNAs in the regulation of cellular redox status and its implications in myocardial ischemia-reperfusion injury. Redox Biol. 2020;36: 101607. https:\/\/doi.org\/10.1016\/J.REDOX.2020.101607.","journal-title":"Redox Biol"},{"issue":"01","key":"10649_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/S-0044-1785234\/ID\/JR2400009-39\/BIB","volume":"11","author":"ND Kolanu","year":"2024","unstructured":"Kolanu ND. CRISPR\u2013Cas9 gene editing: curing genetic diseases by inherited epigenetic modifications. Global Med Genet. 2024;11(01):113\u201322. https:\/\/doi.org\/10.1055\/S-0044-1785234\/ID\/JR2400009-39\/BIB.","journal-title":"Global Med Genet"},{"issue":"1","key":"10649_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01055-2","volume":"7","author":"Y Shi","year":"2022","unstructured":"Shi Y, Zhang H, Huang S, Yin L, Wang F, Luo P, Huang H. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2022;7(1):1\u201328. https:\/\/doi.org\/10.1038\/s41392-022-01055-2.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"10649_CR50","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/BPH.15972","volume":"180","author":"P Ranasinghe","year":"2023","unstructured":"Ranasinghe P, Addison ML, Dear JW, Webb DJ. Small interfering RNA: Discovery, pharmacology and clinical development\u2014an introductory review. Br J Pharmacol. 2023;180(21):2697\u2013720. https:\/\/doi.org\/10.1111\/BPH.15972.","journal-title":"Br J Pharmacol"},{"key":"10649_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-1298-9_1","volume":"2282","author":"M Sioud","year":"2021","unstructured":"Sioud M. RNA interference: story and mechanisms. Methods Mol Biol. 2021;2282:1\u201315. https:\/\/doi.org\/10.1007\/978-1-0716-1298-9_1.","journal-title":"Methods Mol Biol"},{"key":"10649_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/FPLS.2020.01237\/XML\/NLM","volume":"11","author":"P Svoboda","year":"2020","unstructured":"Svoboda P. Key mechanistic principles and considerations concerning RNA interference. Front Plant Sci. 2020;11: 495350. https:\/\/doi.org\/10.3389\/FPLS.2020.01237\/XML\/NLM.","journal-title":"Front Plant Sci"},{"key":"10649_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/ANNUREV-ENTO-011019-025224\/CITE\/REFWORKS","volume":"65","author":"KY Zhu","year":"2020","unstructured":"Zhu KY, Palli SR. Mechanisms, applications, and challenges of insect RNA interference. Ann Rev Entomol. 2020;65:293\u2013311. https:\/\/doi.org\/10.1146\/ANNUREV-ENTO-011019-025224\/CITE\/REFWORKS.","journal-title":"Ann Rev Entomol"},{"key":"10649_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/FPLS.2020.526455\/BIBTEX","volume":"11","author":"J Neumeier","year":"2021","unstructured":"Neumeier J, Meister G. siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Front Plant Sci. 2021;11: 526455. https:\/\/doi.org\/10.3389\/FPLS.2020.526455\/BIBTEX.","journal-title":"Front Plant Sci"},{"issue":"3","key":"10649_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/WRNA.1337","volume":"7","author":"A Alagia","year":"2016","unstructured":"Alagia A, Eritja R. siRNA and RNAi optimization. Wiley Interdiscip Rev: RNA. 2016;7(3):316\u201329. https:\/\/doi.org\/10.1002\/WRNA.1337.","journal-title":"Wiley Interdiscip Rev: RNA"},{"issue":"7","key":"10649_CR56","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3109\/21691401.2015.1102738;PAGE:STRING:ARTICLE\/CHAPTER","volume":"44","author":"B Mansoori","year":"2016","unstructured":"Mansoori B, Mohammadi A, Shir Jang S, Baradaran B. Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA). Artif Cells Nanomedicine Biotechnol. 2016;44(7):1589\u201396. https:\/\/doi.org\/10.3109\/21691401.2015.1102738;PAGE:STRING:ARTICLE\/CHAPTER.","journal-title":"Artif Cells Nanomedicine Biotechnol"},{"key":"10649_CR57","doi-asserted-by":"publisher","unstructured":"Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, \u2026 Gharagouzlo E. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci: IJBS. 2017;13(2):48. https:\/\/doi.org\/10.59566\/ijbs.2017.13048","DOI":"10.59566\/ijbs.2017.13048"},{"issue":"17","key":"10649_CR58","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/J.JMB.2017.07.018","volume":"429","author":"J Sheu-Gruttadauria","year":"2017","unstructured":"Sheu-Gruttadauria J, MacRae IJ. Structural foundations of RNA silencing by argonaute. J Mol Biol. 2017;429(17):2619\u201339. https:\/\/doi.org\/10.1016\/J.JMB.2017.07.018.","journal-title":"J Mol Biol"},{"issue":"6","key":"10649_CR59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/S41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346. https:\/\/doi.org\/10.1038\/S41573-019-0017-4.","journal-title":"Nat Rev Drug Discov"},{"key":"10649_CR60","doi-asserted-by":"publisher","unstructured":"Brown CR, Gupta S, Qin J, Racie T, He G, Lentini S, \u2026 Jadhav V. Investigating the pharmacodynamic durability of GalNAc\u2013siRNA conjugates. Nucleic Acids Res. 2020;48(21):11827\u201311844. https:\/\/doi.org\/10.1093\/NAR\/GKAA670","DOI":"10.1093\/NAR\/GKAA670"},{"key":"10649_CR61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.ADDR.2015.01.007","volume":"87","author":"G Ozcan","year":"2015","unstructured":"Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108\u201319. https:\/\/doi.org\/10.1016\/J.ADDR.2015.01.007.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10649_CR62","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/S40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022;36(5):549\u201371. https:\/\/doi.org\/10.1007\/S40259-022-00549-3.","journal-title":"BioDrugs"},{"issue":"9","key":"10649_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/MTNA.2015.23\/ASSET\/3E144955-8C1C-4A2B-8627-08CEFBB8E76A\/MAIN.ASSETS\/GR3.JPG","volume":"4","author":"JKW Lam","year":"2015","unstructured":"Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4(9): e252. https:\/\/doi.org\/10.1038\/MTNA.2015.23\/ASSET\/3E144955-8C1C-4A2B-8627-08CEFBB8E76A\/MAIN.ASSETS\/GR3.JPG.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"10649_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PCBI.1004656","volume":"11","author":"PJ Kamola","year":"2015","unstructured":"Kamola PJ, Nakano Y, Takahashi T, Wilson PA, Ui-Tei K. The siRNA Non-seed region and its target sequences are auxiliary determinants of off-target effects. PLoS Comput Biol. 2015;11(12): e1004656. https:\/\/doi.org\/10.1371\/JOURNAL.PCBI.1004656.","journal-title":"PLoS Comput Biol"},{"key":"10649_CR65","doi-asserted-by":"publisher","unstructured":"Alagia A, Jorge AF, Avi\u00f1\u00f3 A, Cova TFGG, Crehuet R, Grijalvo S, \u2026 Eritja R. Exploring PAZ\/3\u2032-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Chem Sci. 2018;9(8):2074\u20132086. https:\/\/doi.org\/10.1039\/C8SC00010G","DOI":"10.1039\/C8SC00010G"},{"key":"10649_CR66","doi-asserted-by":"publisher","unstructured":"Bereczki Z, Benczik B, Balogh OM, Marton S, Puhl E, P\u00e9terv\u00e1ri M, \u2026 \u00c1gg B. Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence. Br J Pharmacol. 2024;182(2):340\u2013379. https:\/\/doi.org\/10.1111\/BPH.17302;WGROUP:STRING:PUBLICATION","DOI":"10.1111\/BPH.17302;WGROUP:STRING:PUBLICATION"},{"issue":"2","key":"10649_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/GENES13020319\/S1","volume":"13","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi Y, Tian S, Ui-Tei K. The siRNA off-target effect is determined by base-pairing stabilities of two different regions with opposite effects. Genes. 2022;13(2):319. https:\/\/doi.org\/10.3390\/GENES13020319\/S1.","journal-title":"Genes"},{"key":"10649_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/J.HSR.2024.100157","volume":"11","author":"DD Martinelli","year":"2024","unstructured":"Martinelli DD. Machine learning for siRNA efficiency prediction: a systematic review. Health Sci Rev. 2024;11: 100157. https:\/\/doi.org\/10.1016\/J.HSR.2024.100157.","journal-title":"Health Sci Rev"},{"issue":"4","key":"10649_CR69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/CGT.2016.4","volume":"23","author":"E Fakhr","year":"2016","unstructured":"Fakhr E, Zare F, Teimoori-Toolabi L. Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther. 2016;23(4):73\u201382. https:\/\/doi.org\/10.1038\/CGT.2016.4.","journal-title":"Cancer Gene Ther"},{"key":"10649_CR70","doi-asserted-by":"publisher","unstructured":"Xu X, Zhang B, Wang Y, Shi S, Lv J, Fu Z, \u2026 Song Q. Renal fibrosis in type 2 cardiorenal syndrome: An update on mechanisms and therapeutic opportunities. Biomed Pharmacother. 2023;164:114901. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114901","DOI":"10.1016\/J.BIOPHA.2023.114901"},{"key":"10649_CR71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.COTOX.2017.11.002","volume":"7","author":"K Lingappan","year":"2018","unstructured":"Lingappan K. NF-\u03baB in oxidative stress. Curr Opin Toxicol. 2018;7:81\u20136. https:\/\/doi.org\/10.1016\/J.COTOX.2017.11.002.","journal-title":"Curr Opin Toxicol"},{"key":"10649_CR72","doi-asserted-by":"publisher","first-page":"105030","DOI":"10.1016\/J.PHRS.2020.105030","volume":"159","author":"LP Tavares","year":"2020","unstructured":"Tavares LP, Negreiros-Lima GL, Lima KM, Silva PMRE, Pinho V, Teixeira MM, Sousa LP. Blame the signaling: Role of cAMP for the resolution of inflammation. Pharmacol Res. 2020;159:105030. https:\/\/doi.org\/10.1016\/J.PHRS.2020.105030.","journal-title":"Pharmacol Res"},{"issue":"1","key":"10649_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther. 2022;7(1):1\u201327. https:\/\/doi.org\/10.1038\/s41392-022-01036-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10649_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12929-023-00981-9","volume":"30","author":"H Kang","year":"2023","unstructured":"Kang H, Ga YJ, Kim SH, Cho YH, Kim JW, Kim C, Yeh JY. Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges. J Biomed Sci. 2023;30(1):1\u201318. https:\/\/doi.org\/10.1186\/S12929-023-00981-9.","journal-title":"J Biomed Sci"},{"issue":"12","key":"10649_CR75","doi-asserted-by":"publisher","first-page":"20191732","DOI":"10.1042\/BSR20191732\/221324","volume":"39","author":"J He","year":"2019","unstructured":"He J, Lu Y, Song X, Gong X, Li Y. Inhibition of microRNA-146a attenuated heart failure in myocardial infarction rats. Biosci Rep. 2019;39(12):20191732. https:\/\/doi.org\/10.1042\/BSR20191732\/221324.","journal-title":"Biosci Rep"},{"key":"10649_CR76","unstructured":"RELA RELA proto-oncogene, NF-kB subunit [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved May 31, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=5970"},{"issue":"3","key":"10649_CR77","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/JIMMUN\/VKAE060","volume":"214","author":"Y Cai","year":"2025","unstructured":"Cai Y, Du X, Liu A, Lv M, Sun F, Su P. Transcription factor Rel regulates the transcription of effector genes involved in immune response by cooperating with I\u03baBs in lamprey (Lethenteron reissneri). J Immunol. 2025;214(3):472\u201388. https:\/\/doi.org\/10.1093\/JIMMUN\/VKAE060.","journal-title":"J Immunol"},{"key":"10649_CR78","unstructured":"NFKB1 nuclear factor kappa B subunit 1 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved May 31, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=4790"},{"issue":"15","key":"10649_CR79","doi-asserted-by":"publisher","first-page":"12097","DOI":"10.3390\/IJMS241512097\/S1","volume":"24","author":"C Lin","year":"2023","unstructured":"Lin C, Liu M, Guo J, Jia R. Cryotherapy attenuates inflammation via the lncRNA SNHG1\/miR-9-5p\/NFKB1 regulatory axis in periodontal ligament cells. Int J Mol Sci. 2023;24(15):12097. https:\/\/doi.org\/10.3390\/IJMS241512097\/S1.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10649_CR80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.174977","volume":"9","author":"S Miyazaki-Anzai","year":"2024","unstructured":"Miyazaki-Anzai S, Masuda M, Keenan AL, Shiozaki Y, Miranda JG, Miyazaki M. Activation of the IKK2\/NF-\u03baB pathway in VSMCs inhibits calcified vascular stiffness in CKD. JCI Insight. 2024;9(7): e174977. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.174977.","journal-title":"JCI Insight"},{"key":"10649_CR81","unstructured":"COL4A5 collagen type IV alpha 5 chain [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved May 31, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=1287"},{"issue":"12","key":"10649_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2024.E32904\/ASSET\/270D1D45-19FB-4594-A574-0BFF9B9EF264\/MAIN.ASSETS\/GR3.JPG","volume":"10","author":"M McKenzie","year":"2024","unstructured":"McKenzie M, Lian GY, Pennel KAF, Quinn JA, Jamieson NB, Edwards J. NF\u03baB signalling in colorectal cancer: Examining the central dogma of IKK\u03b1 and IKK\u03b2 signalling. Heliyon. 2024;10(12): e32904. https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E32904\/ASSET\/270D1D45-19FB-4594-A574-0BFF9B9EF264\/MAIN.ASSETS\/GR3.JPG.","journal-title":"Heliyon"},{"issue":"2","key":"10649_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0009428","volume":"5","author":"M Adli","year":"2010","unstructured":"Adli M, Merkhofer E, Cogswell P, Baldwin AS. IKK\u03b1 and IKK\u03b2 each function to regulate NF-\u03baB activation in the TNF-induced\/canonical pathway. PLoS One. 2010;5(2): e9428. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0009428.","journal-title":"PLoS One"},{"key":"10649_CR84","doi-asserted-by":"publisher","unstructured":"Zhang F, Fan L, Zhang H, Huang WJ, Sun D, Pan BB, \u2026 Cao CC. Deficiency of IKK\u03b1 in macrophages mitigates fibrosis progression in the kidney after renal ischemia-reperfusion injury. J Immunol Res. 2021;2021(1):5521051. https:\/\/doi.org\/10.1155\/2021\/5521051","DOI":"10.1155\/2021\/5521051"},{"issue":"4","key":"10649_CR85","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41435-024-00283-6","volume":"25","author":"P Artimovi\u010d","year":"2024","unstructured":"Artimovi\u010d P, \u0160pakov\u00e1 I, Macejkov\u00e1 E, Pribulov\u00e1 T, Rabajdov\u00e1 M, Marekov\u00e1 M, Zavack\u00e1 M. The ability of microRNAs to regulate the immune response in ischemia\/reperfusion inflammatory pathways. Genes Immun. 2024;25(4):277\u201396. https:\/\/doi.org\/10.1038\/s41435-024-00283-6.","journal-title":"Genes Immun"},{"key":"10649_CR86","doi-asserted-by":"publisher","unstructured":"Jiang K, Guo S, Zhang T, Yang Y, Zhao G, Shaukat A, \u2026 Deng G. Downregulation of TLR4 by miR-181a provides negative feedback regulation to lipopolysaccharide-induced inflammation. Front Pharmacol. 2018;9(FEB):334151. https:\/\/doi.org\/10.3389\/FPHAR.2018.00142\/BIBTEX","DOI":"10.3389\/FPHAR.2018.00142\/BIBTEX"},{"key":"10649_CR87","doi-asserted-by":"publisher","unstructured":"Guo Y, Wang F, Wan S, Liu X, Huang Y, Xie M, \u2026 Zhu Y. Endothelium-targeted NF-\u03baB siRNA nanogel for magnetic resonance imaging and visualized-anti-inflammation treatment of atherosclerosis. Biomaterials. 2025;314:122897. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2024.122897","DOI":"10.1016\/J.BIOMATERIALS.2024.122897"},{"key":"10649_CR88","doi-asserted-by":"publisher","unstructured":"Hong HQ, Lu J, Fang XL, Zhang YH, Cai Y, Yuan J, \u2026 Ye JT. G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-\u03baB signaling pathway. Acta Pharmacol Sin. 2018;39(2):184\u2013194. https:\/\/doi.org\/10.1038\/APS.2017.58;KWRD=BIOMEDICINE","DOI":"10.1038\/APS.2017.58;KWRD=BIOMEDICINE"},{"key":"10649_CR89","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/J.JCONREL.2020.01.024","volume":"320","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wu Q, Wang J, Li L, Sun X, Zhang Z, Zhang L. Co-delivery of p38\u03b1 MAPK and p65 siRNA by novel liposomal glomerulus-targeting nano carriers for effective immunoglobulin a nephropathy treatment. J Control Release. 2020;320:457\u201368. https:\/\/doi.org\/10.1016\/J.JCONREL.2020.01.024.","journal-title":"J Control Release"},{"issue":"10","key":"10649_CR90","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/PH13100294","volume":"13","author":"MI Sajid","year":"2020","unstructured":"Sajid MI, Moazzam M, Tiwari RK, Kato S, Cho KY. Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals. 2020;13(10):294. https:\/\/doi.org\/10.3390\/PH13100294.","journal-title":"Pharmaceuticals"},{"key":"10649_CR91","unstructured":"Hamzehloie T, Mojarrad M, Hasanzadeh-Nazarabadi M, Shekouhi S. The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2\u2013P53 interaction for cancer therapy. Iran J Med Sci. 2012;37(1);3. Retrieved from https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3470295\/"},{"key":"10649_CR92","doi-asserted-by":"publisher","unstructured":"Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, \u2026 Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19(18):2122-2137. https:\/\/doi.org\/10.1101\/gad.1339905","DOI":"10.1101\/gad.1339905"},{"issue":"9","key":"10649_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00018-022-04505-W\/METRICS","volume":"79","author":"JM Overstreet","year":"2022","unstructured":"Overstreet JM, Gifford CC, Tang J, Higgins PJ, Samarakoon R. Emerging role of tumor suppressor p53 in acute and chronic kidney diseases. Cell Mol Life Sci. 2022;79(9):1\u201312. https:\/\/doi.org\/10.1007\/S00018-022-04505-W\/METRICS.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10649_CR94","doi-asserted-by":"publisher","first-page":"244","DOI":"10.23876\/J.KRCP.20.082","volume":"39","author":"D Bhatia","year":"2020","unstructured":"Bhatia D, Capili A, Choi ME. Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches. Kidney Res Clin Pract. 2020;39(3):244. https:\/\/doi.org\/10.23876\/J.KRCP.20.082.","journal-title":"Kidney Res Clin Pract."},{"issue":"6","key":"10649_CR95","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/BIOM15060794","volume":"15","author":"T Eleftheriadis","year":"2025","unstructured":"Eleftheriadis T, Xu D, Zhang X, Pang J, Li Y, Peng Z. Mechanisms of acute kidney injury-chronic kidney disease transition: unraveling maladaptive repair and therapeutic opportunities. Biomolecules. 2025;15(6):794. https:\/\/doi.org\/10.3390\/BIOM15060794.","journal-title":"Biomolecules"},{"key":"10649_CR96","doi-asserted-by":"publisher","unstructured":"Tang C, Ma Z, Zhu J, Liu Z, Liu Y, Liu Y, \u2026 Dong Z. P53 in kidney injury and repair: mechanism and therapeutic potentials. Pharmacol Ther. 2019;195:5-12. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2018.10.013","DOI":"10.1016\/J.PHARMTHERA.2018.10.013"},{"key":"10649_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.981152\/EPUB","volume":"13","author":"GHH Chan","year":"2022","unstructured":"Chan GHH, Chan E, Kwok CTK, Leung GPH, Lee SMY, Seto SW. The role of p53 in the alternation of vascular functions. Front Pharmacol. 2022;13: 981152. https:\/\/doi.org\/10.3389\/FPHAR.2022.981152\/EPUB.","journal-title":"Front Pharmacol"},{"key":"10649_CR98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/J.YJMCC.2019.05.008","volume":"132","author":"P Zhabyeyev","year":"2019","unstructured":"Zhabyeyev P, McLean B, Chen X, Vanhaesebroeck B, Oudit GY. Inhibition of PI3Kinase-\u03b1 is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2+ release in murine hearts. J Mol Cell Cardiol. 2019;132:98\u2013109. https:\/\/doi.org\/10.1016\/J.YJMCC.2019.05.008.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10649_CR99","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1161\/CIRCRESAHA.117.311311\/ASSET\/DB9D33AC-F1D2-4408-86EF-9CCE5D14317A\/ASSETS\/GRAPHIC\/205FIG02.JPG","volume":"123","author":"T Lucas","year":"2018","unstructured":"Lucas T, Bonauer A, Dimmeler S. RNA therapeutics in cardiovascular disease. Circ Res. 2018;123(2):205\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311311\/ASSET\/DB9D33AC-F1D2-4408-86EF-9CCE5D14317A\/ASSETS\/GRAPHIC\/205FIG02.JPG.","journal-title":"Circ Res"},{"key":"10649_CR100","doi-asserted-by":"publisher","unstructured":"Bao YN, Yang Q, Shen XL, Yu WK, Zhou L, Zhu QR, \u2026 Cao G. Targeting tumor suppressor p53 for organ fibrosis therapy. Cell Death Dis. 2024;15(5):1-11. https:\/\/doi.org\/10.1038\/s41419-024-06702-w","DOI":"10.1038\/s41419-024-06702-w"},{"key":"10649_CR101","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez Borrero, L. J., & El-Deiry, W. S. (2021). Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1876(1), 188556. https:\/\/doi.org\/10.1016\/J.BBCAN.2021.188556","DOI":"10.1016\/J.BBCAN.2021.188556"},{"issue":"8","key":"10649_CR102","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/CIRCRESAHA.122.321751\/ASSET\/0506C851-8C50-4A9C-9A65-B98C3A5FD7E7\/ASSETS\/GRAPHIC\/CIRCRESAHA.122.321751.FIG07.JPG","volume":"132","author":"S Hobson","year":"2023","unstructured":"Hobson S, Arefin S, Witasp A, Hernandez L, Kublickiene K, Shiels PG, Stenvinkel P. Accelerated vascular aging in chronic kidney disease: the potential for novel therapies. Circ Res. 2023;132(8):950\u201369. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321751\/ASSET\/0506C851-8C50-4A9C-9A65-B98C3A5FD7E7\/ASSETS\/GRAPHIC\/CIRCRESAHA.122.321751.FIG07.JPG.","journal-title":"Circ Res"},{"issue":"12","key":"10649_CR103","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1681\/ASN.2013121270","volume":"25","author":"Y Ying","year":"2014","unstructured":"Ying Y, Kim J, Westphal SN, Long KE, Padanilam BJ. Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol. 2014;25(12):2707\u201316. https:\/\/doi.org\/10.1681\/ASN.2013121270.","journal-title":"J Am Soc Nephrol"},{"key":"10649_CR104","doi-asserted-by":"publisher","unstructured":"McCullough PA, Kellum JA, Haase M, M\u00fcller C, Damman K, Murray PT, \u2026 Ronco C. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol. 2013;182:82\u201398. https:\/\/doi.org\/10.1159\/000349966","DOI":"10.1159\/000349966"},{"key":"10649_CR105","doi-asserted-by":"publisher","unstructured":"Martin SE, Jones TL, Thomas CL, Lorenzi PL, Nguyen DA, Runfola T, \u2026 Caplen NJ. Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res. 2007;35(8):e57\u2013e57. https:\/\/doi.org\/10.1093\/NAR\/GKM141","DOI":"10.1093\/NAR\/GKM141"},{"key":"10649_CR106","doi-asserted-by":"publisher","unstructured":"Adamcova M, Parova H, Lencova-Popelova O, Kollarova-Brazdova P, Baranova I, Slavickova, M, \u2026 Sterba M. Cardiac miRNA expression during the development of chronic anthracycline-induced cardiomyopathy using an experimental rabbit model. Front Pharmacol. 2023;14:1298172. https:\/\/doi.org\/10.3389\/FPHAR.2023.1298172\/BIBTEX","DOI":"10.3389\/FPHAR.2023.1298172\/BIBTEX"},{"issue":"10","key":"10649_CR107","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/CELLS11101631","volume":"11","author":"C Capaccia","year":"2022","unstructured":"Capaccia C, Diverio S, Zampini D, Guelfi G. The complex interaction between P53 and miRNAs joins new awareness in physiological stress responses. Cells. 2022;11(10):1631. https:\/\/doi.org\/10.3390\/CELLS11101631.","journal-title":"Cells"},{"key":"10649_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.00726\/BIBTEX","volume":"11","author":"CK Huang","year":"2020","unstructured":"Huang CK, B\u00e4r C, Thum T. miR-21, mediator, and potential therapeutic target in the cardiorenal syndrome. Front Pharmacol. 2020;11: 442028. https:\/\/doi.org\/10.3389\/FPHAR.2020.00726\/BIBTEX.","journal-title":"Front Pharmacol"},{"issue":"3","key":"10649_CR109","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/BIOMEDICINES9030303","volume":"9","author":"F Cart\u00f3n-Garc\u00eda","year":"2021","unstructured":"Cart\u00f3n-Garc\u00eda F, Saande CJ, Meraviglia-Crivelli D, Aldabe R, Pastor F. Oligonucleotide-based therapies for renal diseases. Biomedicines. 2021;9(3):303. https:\/\/doi.org\/10.3390\/BIOMEDICINES9030303.","journal-title":"Biomedicines"},{"key":"10649_CR110","doi-asserted-by":"publisher","unstructured":"Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, \u2026 Feinstein E. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol. 2009;20(8):1754\u20131764. https:\/\/doi.org\/10.1681\/ASN.2008111204","DOI":"10.1681\/ASN.2008111204"},{"issue":"1","key":"10649_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):1\u201325. https:\/\/doi.org\/10.1038\/s41392-020-0207-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10649_CR112","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/TP.0000000000001557","volume":"101","author":"M Finsterbusch","year":"2017","unstructured":"Finsterbusch M, Kitching AR, Hickey MJ. Imaging leukocyte responses in the kidney. Transplantation. 2017;101(3):506\u201316. https:\/\/doi.org\/10.1097\/TP.0000000000001557.","journal-title":"Transplantation"},{"key":"10649_CR113","doi-asserted-by":"publisher","unstructured":"Liang C, Weitao T, Zhou L, Guo P. Translation of the longterm fundamental studies on viral DNA packaging motors into nanotechnology and nanomedicine. Biomotors Nanobiotechnology Appl. 2023;281-319. https:\/\/doi.org\/10.1201\/9780429203367-27\/TRANSLATION-LONG-TERM-FUNDAMENTAL-STUDIES-VIRAL-DNA-PACKAGING-MOTORS-NANOTECHNOLOGY-NANOMEDICINE-CHENXI-LIANG-TAO-WEITAO-LIXIA-ZHOU-PEIXUAN-GUO","DOI":"10.1201\/9780429203367-27\/TRANSLATION-LONG-TERM-FUNDAMENTAL-STUDIES-VIRAL-DNA-PACKAGING-MOTORS-NANOTECHNOLOGY-NANOMEDICINE-CHENXI-LIANG-TAO-WEITAO-LIXIA-ZHOU-PEIXUAN-GUO"},{"key":"10649_CR114","doi-asserted-by":"publisher","unstructured":"Wei PS, Thota N, John G, Chang E, Lee S, Wang Y, \u2026 Mei KC. Enhancing RNA-lipid nanoparticle delivery: organ- and cell-specificity and barcoding strategies. J Control Release. 2024;375:366-388. https:\/\/doi.org\/10.1016\/J.JCONREL.2024.08.030","DOI":"10.1016\/J.JCONREL.2024.08.030"},{"issue":"1","key":"10649_CR115","doi-asserted-by":"publisher","first-page":"2483990","DOI":"10.1080\/0886022X.2025.2483990;WGROUP:STRING:PUBLICATION","volume":"47","author":"P Rani","year":"2025","unstructured":"Rani P, Koulmane Laxminarayana SL, Swaminathan SM, Nagaraju SP, Bhojaraja MV, Shetty S, Kanakalakshmi ST. TGF-\u03b2: elusive target in diabetic kidney disease. Ren Fail. 2025;47(1):2483990. https:\/\/doi.org\/10.1080\/0886022X.2025.2483990;WGROUP:STRING:PUBLICATION.","journal-title":"Ren Fail"},{"issue":"7","key":"10649_CR116","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.7150\/IJBS.71595","volume":"18","author":"W Wu","year":"2022","unstructured":"Wu W, Wang X, Yu X, Lan HY. Smad3 signatures in renal inflammation and fibrosis. Int J Biol Sci. 2022;18(7):2795. https:\/\/doi.org\/10.7150\/IJBS.71595.","journal-title":"Int J Biol Sci"},{"key":"10649_CR117","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/J.MAM.2018.07.001","volume":"65","author":"NG Frangogiannis","year":"2019","unstructured":"Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019;65:70\u201399. https:\/\/doi.org\/10.1016\/J.MAM.2018.07.001.","journal-title":"Mol Aspects Med"},{"key":"10649_CR118","doi-asserted-by":"publisher","unstructured":"Saadat S, Noureddini M, Mahjoubin-Tehran M, Nazemi S, Shojaie L, Aschner M, \u2026 Mirzaei H. Pivotal role of TGF-\u03b2\/Smad signaling in cardiac fibrosis: non-coding RNAs as effectual players. Front Cardiovasc Med. 2021;7:588347. https:\/\/doi.org\/10.3389\/FCVM.2020.588347\/XML\/NLM","DOI":"10.3389\/FCVM.2020.588347\/XML\/NLM"},{"issue":"MAR","key":"10649_CR119","doi-asserted-by":"publisher","first-page":"134394","DOI":"10.3389\/FPHYS.2015.00082\/XML\/NLM","volume":"6","author":"XM Meng","year":"2015","unstructured":"Meng XM, Tang PMK, Li J, Lan HY. TGF-\u00df\/Smad signaling in renal fibrosis. Front Physiol. 2015;6(MAR):134394. https:\/\/doi.org\/10.3389\/FPHYS.2015.00082\/XML\/NLM.","journal-title":"Front Physiol"},{"issue":"2","key":"10649_CR120","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3892\/MMR.2024.13267","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Zou Y, Kantapan J, Su H, Wang L, Dechsupa N. TGF-\u03b2\/Smad signaling in chronic kidney disease: exploring post-translational regulatory perspectives (Review). Mol Med Rep. 2024;30(2):143. https:\/\/doi.org\/10.3892\/MMR.2024.13267.","journal-title":"Mol Med Rep"},{"issue":"2","key":"10649_CR121","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/BIOMEDICINES10020283","volume":"10","author":"CT Su","year":"2022","unstructured":"Su CT, See DHW, Huang JW. Lipid-based nanocarriers in renal RNA therapy. Biomedicines. 2022;10(2):283. https:\/\/doi.org\/10.3390\/BIOMEDICINES10020283.","journal-title":"Biomedicines"},{"key":"10649_CR122","doi-asserted-by":"publisher","unstructured":"Pang Y, Xu Y, Chen Q, Cheng K, Ling Y, Jang J, \u2026 Zhu W. FLRT3 and TGF-\u03b2\/SMAD4 signalling: Impacts on apoptosis, autophagy and ion channels in supraventricular tachycardia. J Cell Mol Med. 2024;28(7):e18237. https:\/\/doi.org\/10.1111\/JCMM.18237;CTYPE:STRING:JOURNAL","DOI":"10.1111\/JCMM.18237;CTYPE:STRING:JOURNAL"},{"key":"10649_CR123","doi-asserted-by":"publisher","unstructured":"Qin W, Chung ACK, Huang XR, Meng XM, Hui DSC, Yu CM, \u2026 Lan HY. TGF-\u03b2\/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011;22(8):1462\u20131474. https:\/\/doi.org\/10.1681\/ASN.2010121308","DOI":"10.1681\/ASN.2010121308"},{"issue":"4","key":"10649_CR124","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/S40139-014-0060-0\/TABLES\/1","volume":"2","author":"PMK Tang","year":"2014","unstructured":"Tang PMK, Lan HY. MicroRNAs in TGF-\u03b2\/Smad-mediated tissue fibrosis. Curr Pathobiology Rep. 2014;2(4):235\u201343. https:\/\/doi.org\/10.1007\/S40139-014-0060-0\/TABLES\/1.","journal-title":"Curr Pathobiology Rep"},{"issue":"2","key":"10649_CR125","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.YMTHE.2023.12.009\/ASSET\/9662D226-D4AA-4453-A26D-4FDEBFD9377A\/MAIN.ASSETS\/GR3.JPG","volume":"32","author":"YY Gu","year":"2024","unstructured":"Gu YY, Liu XS, Lan HY. Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs. Mol Ther. 2024;32(2):313\u201324. https:\/\/doi.org\/10.1016\/J.YMTHE.2023.12.009\/ASSET\/9662D226-D4AA-4453-A26D-4FDEBFD9377A\/MAIN.ASSETS\/GR3.JPG.","journal-title":"Mol Ther"},{"key":"10649_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJCRP.2024.200355","volume":"24","author":"RL Zhang","year":"2025","unstructured":"Zhang RL, Wang WM, Li JQ, Li RW, Zhang J, Wu Y, Liu Y. The role of miR-155 in cardiovascular diseases: potential diagnostic and therapeutic targets. Int J Cardiol Cardiovasc Risk Prev. 2025;24: 200355. https:\/\/doi.org\/10.1016\/J.IJCRP.2024.200355.","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10649_CR127","doi-asserted-by":"publisher","first-page":"1196104","DOI":"10.3389\/FIMMU.2023.1196104\/XML\/NLM","volume":"14","author":"L Zapata-Mart\u00ednez","year":"2023","unstructured":"Zapata-Mart\u00ednez L, \u00c1guila S, de los Reyes-Garc\u00eda AM, Carrillo-Tornel S, Lozano ML, Gonz\u00e1lez-Conejero R, Mart\u00ednez C. Inflammatory microRNAs in cardiovascular pathology: another brick in the wall. Front Immunol. 2023;14:1196104. https:\/\/doi.org\/10.3389\/FIMMU.2023.1196104\/XML\/NLM.","journal-title":"Front Immunol"},{"key":"10649_CR128","doi-asserted-by":"publisher","unstructured":"Marahrens B, Schulze A, Wysocki J, Lin MH, Ye M, Kanwar YS, \u2026 Batlle D. Knockout of aminopeptidase A in mice causes functional alterations and morphological glomerular basement membrane changes in the kidneys. Kidney Int. 2021;99(4):900-913. https:\/\/doi.org\/10.1016\/J.KINT.2020.11.012","DOI":"10.1016\/J.KINT.2020.11.012"},{"key":"10649_CR129","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Cerd\u00e1 S, Molinaro G, Tello RP, Correia A, Waris E, Hirvonen J, \u2026 Santos HA. Antifibrotic and pro-regenerative effects of SMAD3 siRNA and collagen I mRNA-loaded lipid nanoparticles in human tenocytes. ACS Appl Nano Mater. 2024;7(15):17736\u201317747. https:\/\/doi.org\/10.1021\/ACSANM.4C02996\/ASSET\/IMAGES\/LARGE\/AN4C02996_0009.JPEG","DOI":"10.1021\/ACSANM.4C02996\/ASSET\/IMAGES\/LARGE\/AN4C02996_0009.JPEG"},{"key":"10649_CR130","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.omtm.2020.08.003","volume":"18","author":"J Meng","year":"2020","unstructured":"Meng J, Qin Y, Chen J, Wei L, Huang XR, Yu X, Lan HY. Treatment of hypertensive heart disease by targeting Smad3 signaling in mice. Mol Ther Methods Clin Dev. 2020;18:791\u2013802. https:\/\/doi.org\/10.1016\/j.omtm.2020.08.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10649_CR131","doi-asserted-by":"publisher","unstructured":"Dong L, Li JC, Hu ZJ, Huang XR, Wang L, Wang HL, \u2026 Yang SJ. Deletion of Smad3 protects against diabetic myocardiopathy in db\/db mice. J Cell Mol Med. 2021;25(10):4860\u20134869. https:\/\/doi.org\/10.1111\/JCMM.16464","DOI":"10.1111\/JCMM.16464"},{"key":"10649_CR132","doi-asserted-by":"publisher","unstructured":"Li J, Sun YBY, Chen W, Fan J, Li S, Qu X, \u2026 Yu X. Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS . EMBO Rep. 2020;21(2). https:\/\/doi.org\/10.15252\/EMBR.201948781\/SUPPL_FILE\/EMBR201948781-SUP-0001-EVFIGS.PDF","DOI":"10.15252\/EMBR.201948781\/SUPPL_FILE\/EMBR201948781-SUP-0001-EVFIGS.PDF"},{"key":"10649_CR133","unstructured":"SMAD3 SMAD family member 3 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=4088"},{"issue":"9","key":"10649_CR134","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1097\/MS9.0000000000001118","volume":"85","author":"N Aderinto","year":"2023","unstructured":"Aderinto N, Abdulbasit MO, Olatunji G, Edun M, Aboderin G. The promise of RNA-based therapeutics in revolutionizing heart failure management \u2013 a narrative review of current evidence. Ann Med Surg. 2023;85(9):4442\u201353. https:\/\/doi.org\/10.1097\/MS9.0000000000001118.","journal-title":"Ann Med Surg"},{"key":"10649_CR135","doi-asserted-by":"publisher","unstructured":"Wang W, Li Y, Zhang C, Zhou H, Li C, Cheng R, \u2026 Chen Y. Small extracellular vesicles from young healthy human plasma inhibit cardiac fibrosis after myocardial infarction via miR-664a-3p targeting SMAD4. Int J Nanomedicine. 2025;20:557\u2013579. https:\/\/doi.org\/10.2147\/IJN.S488368","DOI":"10.2147\/IJN.S488368"},{"issue":"1","key":"10649_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-024-02972-W","volume":"22","author":"E Haghighi","year":"2024","unstructured":"Haghighi E, Abolmaali SS, Dehshahri A, Ali S, Shaegh M, Azarpira N, Tamaddon AM. Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach. J Nanobiotechnology. 2024;22(1):1\u201355. https:\/\/doi.org\/10.1186\/S12951-024-02972-W.","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"10649_CR137","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2144\/03353ST01;CTYPE:STRING:JOURNAL","volume":"35","author":"SD Lawrence","year":"2003","unstructured":"Lawrence SD, Novak NG, Slack JM. Epitope tagging: a monoclonal antibody specific for recombinant fusion proteins in plants. Biotechniques. 2003;35(3):488\u201392. https:\/\/doi.org\/10.2144\/03353ST01;CTYPE:STRING:JOURNAL.","journal-title":"Biotechniques"},{"key":"10649_CR138","doi-asserted-by":"publisher","unstructured":"Yoshida S, Yoshida T, Inukai K, Kato K, Yura Y, Hattori T, \u2026 Takefuji M. Protein kinase N promotes cardiac fibrosis in heart failure by fibroblast-to-myofibroblast conversion. Nature Commun. 2024;15(1):1\u201316. https:\/\/doi.org\/10.1038\/s41467-024-52068-0","DOI":"10.1038\/s41467-024-52068-0"},{"key":"10649_CR139","doi-asserted-by":"publisher","unstructured":"Zeng L, Zhang X, Huang Z, Song S, Li M, Wang T, \u2026 Ge J. Ubiquitin proteasome system in cardiac fibrosis. J Adv Res. 2024;. https:\/\/doi.org\/10.1016\/J.JARE.2024.12.006","DOI":"10.1016\/J.JARE.2024.12.006"},{"key":"10649_CR140","doi-asserted-by":"publisher","unstructured":"Chen Y, Dai R, Cheng M, Wang W, Liu C, Cao Z, \u2026 Zhang L. Status and role of the ubiquitin\u2013proteasome system in renal fibrosis. Biomed Pharmacother. 2024;178:117210. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.117210","DOI":"10.1016\/J.BIOPHA.2024.117210"},{"key":"10649_CR141","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/J.TRSL.2018.09.003","volume":"205","author":"SK Shukla","year":"2019","unstructured":"Shukla SK, Rafiq K. Proteasome biology and therapeutics in cardiac diseases. Transl Res. 2019;205:64\u201376. https:\/\/doi.org\/10.1016\/J.TRSL.2018.09.003.","journal-title":"Transl Res"},{"key":"10649_CR142","doi-asserted-by":"publisher","unstructured":"Makino SI, Shirata N, Trejo JAO, Yamamoto-Nonaka K, Yamada H, Miyake T, \u2026 Asanuma K. Impairment of proteasome function in podocytes leads to CKD. J Am Soc Nephrol. 2021;32(3):597\u2013613. https:\/\/doi.org\/10.1681\/ASN.2019101025","DOI":"10.1681\/ASN.2019101025"},{"issue":"MAR","key":"10649_CR143","doi-asserted-by":"publisher","first-page":"443912","DOI":"10.3389\/FIMMU.2019.00815\/XML\/NLM","volume":"10","author":"N Song","year":"2019","unstructured":"Song N, Thaiss F, Guo L. NF\u03baB and kidney injury. Front Immunol. 2019;10(MAR):443912. https:\/\/doi.org\/10.3389\/FIMMU.2019.00815\/XML\/NLM.","journal-title":"Front Immunol."},{"key":"10649_CR144","doi-asserted-by":"publisher","unstructured":"Bhat SA, Vasi Z, Adhikari R, Gudur A, Ali A, Jiang L, \u2026 Kuchay S. Ubiquitin proteasome system in immune regulation and therapeutics. Curr Opin Pharmacol. 2022;67:102310. https:\/\/doi.org\/10.1016\/J.COPH.2022.102310","DOI":"10.1016\/J.COPH.2022.102310"},{"issue":"9","key":"10649_CR145","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/NRI.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC. The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545\u201358. https:\/\/doi.org\/10.1038\/NRI.2017.52.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10649_CR146","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/JLB.3MIR0817-346RRR","volume":"103","author":"DE Rothschild","year":"2018","unstructured":"Rothschild DE, McDaniel DK, Ringel-Scaia VM, Allen IC. Modulating inflammation through the negative regulation of NF-\u03baB signaling. J Leukoc Biol. 2018;103(6):1131\u201350. https:\/\/doi.org\/10.1002\/JLB.3MIR0817-346RRR.","journal-title":"J Leukoc Biol"},{"key":"10649_CR147","doi-asserted-by":"publisher","unstructured":"Boumil EF, Castro N, Phillips AT, Chatterton JE, McCauley SM, Wolfson AD, \u2026 Bernstein AM. USP10 targeted self-deliverable siRNA to prevent scarring in the cornea. Mol Ther Nucleic Acids. 2020;21:1029\u20131043. https:\/\/doi.org\/10.1016\/J.OMTN.2020.07.032\/ATTACHMENT\/F6DAF92D-B31F-49C5-828B-374F5BDAA37F\/MMC2.PDF","DOI":"10.1016\/J.OMTN.2020.07.032\/ATTACHMENT\/F6DAF92D-B31F-49C5-828B-374F5BDAA37F\/MMC2.PDF"},{"issue":"3","key":"10649_CR148","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/BIOM13030568","volume":"13","author":"Z Kuang","year":"2023","unstructured":"Kuang Z, Wu J, Tan Y, Zhu G, Li J, Wu M. MicroRNA in the diagnosis and treatment of doxorubicin-induced cardiotoxicity. Biomolecules. 2023;13(3):568. https:\/\/doi.org\/10.3390\/BIOM13030568.","journal-title":"Biomolecules"},{"key":"10649_CR149","unstructured":"ITCH itchy E3 ubiquitin protein ligase [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=83737"},{"key":"10649_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.TRSL.2022.02.001","volume":"245","author":"RUTH Fernandez-Ruiz","year":"2022","unstructured":"Fernandez-Ruiz RUTH, Belmont HM. The role of anticomplement therapy in lupus nephritis. Transl Res. 2022;245:1\u201317. https:\/\/doi.org\/10.1016\/J.TRSL.2022.02.001.","journal-title":"Transl Res"},{"issue":"1","key":"10649_CR151","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/BIOMEDICINES12010171\/S1","volume":"12","author":"S Bakhashab","year":"2024","unstructured":"Bakhashab S, O\u2019Neill J, Barber R, Arden C, Weaver JU. Upregulation of anti-angiogenic miR-106b-3p correlates negatively with IGF-1 and vascular health parameters in a model of subclinical cardiovascular disease: study with metformin therapy. Biomedicines. 2024;12(1):171. https:\/\/doi.org\/10.3390\/BIOMEDICINES12010171\/S1.","journal-title":"Biomedicines"},{"issue":"10","key":"10649_CR152","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.7150\/IJBS.93644","volume":"20","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou Y, Jiang C, Jian N, Wang J. Crosstalk of ubiquitin system and non-coding RNA in fibrosis. Int J Biol Sci. 2024;20(10):3802. https:\/\/doi.org\/10.7150\/IJBS.93644.","journal-title":"Int J Biol Sci"},{"key":"10649_CR153","doi-asserted-by":"publisher","unstructured":"Ding Y, Chen Q-B, Xu H, Adi D, Ding Y-W, Luo W-J, \u2026 Lu X-Y. siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice. J Lipid Res. 2024;65(9):100626. https:\/\/doi.org\/10.1016\/J.JLR.2024.100626","DOI":"10.1016\/J.JLR.2024.100626"},{"key":"10649_CR154","unstructured":"USP10 ubiquitin specific peptidase 10 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=9100"},{"issue":"3","key":"10649_CR155","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/J.CELL.2009.12.032\/ATTACHMENT\/89A85C8D-F121-4DF6-B55F-C15DD81E25D9\/MMC1.PDF","volume":"140","author":"J Yuan","year":"2010","unstructured":"Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140(3):384\u201396. https:\/\/doi.org\/10.1016\/J.CELL.2009.12.032\/ATTACHMENT\/89A85C8D-F121-4DF6-B55F-C15DD81E25D9\/MMC1.PDF.","journal-title":"Cell"},{"key":"10649_CR156","doi-asserted-by":"crossref","unstructured":"MicroRNA-29a induces insulin resistance by targeting PPAR\u03b4 in skeletal muscle cells. (n.d.). Retrieved June 1, 2025, from https:\/\/www.spandidos-publications.com\/ijmm\/37\/4\/931","DOI":"10.3892\/ijmm.2016.2499"},{"key":"10649_CR157","unstructured":"USP20 ubiquitin specific peptidase 20 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=10868"},{"key":"10649_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2024.116413","volume":"173","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yang Z, Wang S, Wang X, Mao J. Targeting MAPK-ERK\/JNK pathway: a potential intervention mechanism of myocardial fibrosis in heart failure. Biomed Pharmacother. 2024;173: 116413. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.116413.","journal-title":"Biomed Pharmacother"},{"key":"10649_CR159","doi-asserted-by":"publisher","unstructured":"Jubaidi FF, Zainalabidin S, Taib IS, Abdul Hamid Z, Mohamad Anuar NN, Jalil J, \u2026 Budin SB. The role of PKC-MAPK signalling pathways in the development of hyperglycemia-induced cardiovascular complications. Int J Mol Sci. 2022;23(15):8582. https:\/\/doi.org\/10.3390\/IJMS23158582","DOI":"10.3390\/IJMS23158582"},{"key":"10649_CR160","doi-asserted-by":"publisher","unstructured":"Ansari MA, Khan FB, Safdari HA, Almatroudi A, Alzohairy MA, Safdari M, \u2026 Hoque M. Prospective therapeutic potential of Tanshinone IIA: an updated overview. Pharmacol Res. 2021;164:105364. https:\/\/doi.org\/10.1016\/J.PHRS.2020.105364","DOI":"10.1016\/J.PHRS.2020.105364"},{"issue":"2","key":"10649_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHYPLU.2024.100564","volume":"4","author":"R Sahu","year":"2024","unstructured":"Sahu R, Rawal RK. Modulation of the c-JNK\/p38-MAPK signaling pathway: investigating the therapeutic potential of natural products in hypertension. Phytomedicine Plus. 2024;4(2): 100564. https:\/\/doi.org\/10.1016\/J.PHYPLU.2024.100564.","journal-title":"Phytomedicine Plus"},{"key":"10649_CR162","doi-asserted-by":"publisher","unstructured":"Novotortsev VK, Kukushkin ME, Tafeenko VA, Skvortsov DA, Kalinina MA, Timoshenko RV, \u2026 Beloglazkina EK. Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: synthesis, cytotoxicity and ROS generation ability. Int J Mol Sci. 2021;22(5):2613. https:\/\/doi.org\/10.3390\/IJMS22052613","DOI":"10.3390\/IJMS22052613"},{"issue":"4","key":"10649_CR163","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/GENES16040381","volume":"16","author":"M Shameem","year":"2025","unstructured":"Shameem M, Olson SL, de Velasco EMF, Kumar A, Singh BN. Cardiac fibroblasts: helping or hurting. Genes. 2025;16(4):381. https:\/\/doi.org\/10.3390\/GENES16040381.","journal-title":"Genes"},{"issue":"19","key":"10649_CR164","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.3390\/IJMS21197412","volume":"21","author":"R Romero-Becerra","year":"2020","unstructured":"Romero-Becerra R, Santamans AM, Folgueira C, Sabio G. p38 MAPK pathway in the heart: new insights in health and disease. Int J Mol Sci. 2020;21(19):7412. https:\/\/doi.org\/10.3390\/IJMS21197412.","journal-title":"Int J Mol Sci"},{"issue":"JUL","key":"10649_CR165","doi-asserted-by":"publisher","first-page":"355257","DOI":"10.3389\/FPHAR.2018.00715\/XML\/NLM","volume":"9","author":"M Shvedova","year":"2018","unstructured":"Shvedova M, Anfinogenova Y, Atochina-Vasserman EN, Schepetkin IA, Atochin DN. c-Jun N-terminal kinases (JNKs) in myocardial and cerebral ischemia\/reperfusion injury. Front Pharmacol. 2018;9(JUL):355257. https:\/\/doi.org\/10.3389\/FPHAR.2018.00715\/XML\/NLM.","journal-title":"Front Pharmacol"},{"issue":"1","key":"10649_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10020-023-00657-Y\/FIGURES\/7","volume":"29","author":"Y Tao","year":"2023","unstructured":"Tao Y, Tang C, Wei J, Shan Y, Fang X, Li Y. Nr4a1 promotes renal interstitial fibrosis by regulating the p38 MAPK phosphorylation. Mol Med. 2023;29(1):1\u201312. https:\/\/doi.org\/10.1186\/S10020-023-00657-Y\/FIGURES\/7.","journal-title":"Mol Med"},{"issue":"4","key":"10649_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-04856-z","volume":"13","author":"B Liu","year":"2022","unstructured":"Liu B, Sun T, Li H, Qiu S, Li Y, Zhang D. Proximal tubular RAGE mediated the renal fibrosis in UUO model mice via upregulation of autophagy. Cell Death Dis. 2022;13(4):1\u201312. https:\/\/doi.org\/10.1038\/s41419-022-04856-z.","journal-title":"Cell Death Dis"},{"key":"10649_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2019.105835","volume":"76","author":"W Pan","year":"2019","unstructured":"Pan W, Wei N, Xu W, Wang G, Gong F, Li N. MicroRNA-124 alleviates the lung injury in mice with septic shock through inhibiting the activation of the MAPK signaling pathway by downregulating MAPK14. Int Immunopharmacol. 2019;76: 105835. https:\/\/doi.org\/10.1016\/J.INTIMP.2019.105835.","journal-title":"Int Immunopharmacol"},{"key":"10649_CR169","doi-asserted-by":"publisher","unstructured":"Li J, Liang C, Zhang ZK, Pan X, Peng S, Lee WS, \u2026 Zhang BT. TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis. Cell Discov. 2017;3(1):1\u201321. https:\/\/doi.org\/10.1038\/CELLDISC.2017.23;SUBJMETA=250,262,304,631,80;KWRD=INNATE+IMMUNITY,MECHANISMS+OF+DISEASE","DOI":"10.1038\/CELLDISC.2017.23;SUBJMETA=250,262,304,631,80;KWRD=INNATE+IMMUNITY,MECHANISMS+OF+DISEASE"},{"key":"10649_CR170","unstructured":"MAPK14 mitogen-activated protein kinase 14 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=1432"},{"key":"10649_CR171","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.2147\/OTT.S183600;PAGE:STRING:ARTICLE\/CHAPTER","volume":"11","author":"W Yu","year":"2018","unstructured":"Yu W, Liang X, Li X, Zhang Y, Sun Z, Liu Y, Wang J. MicroRNA-195: a review of its role in cancers. Onco Targets Ther. 2018;11:7109\u201323. https:\/\/doi.org\/10.2147\/OTT.S183600;PAGE:STRING:ARTICLE\/CHAPTER.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10649_CR172","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/JCPH.2337;JOURNAL:JOURNAL:15524604C;PAGE:STRING:ARTICLE\/CHAPTER","volume":"64","author":"G An","year":"2024","unstructured":"An G. Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs. J Clin Pharmacol. 2024;64(1):45\u201357. https:\/\/doi.org\/10.1002\/JCPH.2337;JOURNAL:JOURNAL:15524604C;PAGE:STRING:ARTICLE\/CHAPTER.","journal-title":"J Clin Pharmacol"},{"key":"10649_CR173","unstructured":"MAPK8 mitogen-activated protein kinase 8 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=5599"},{"key":"10649_CR174","unstructured":"MAPK9 mitogen-activated protein kinase 9 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=DetailsSearch&Term=5601"},{"key":"10649_CR175","unstructured":"MAP3K7 mitogen-activated protein kinase kinase kinase 7 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene\/6885"},{"key":"10649_CR176","doi-asserted-by":"publisher","unstructured":"Martin SE, Wu Z-H, Gehlhaus K, Jones TL, Zhang Y-W, Guha R, \u2026 Caplen NJ. RNAi screening identifies TAK1 as a Potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets. 2011;11(8):976\u2013986. https:\/\/doi.org\/10.2174\/156800911797264734","DOI":"10.2174\/156800911797264734"},{"key":"10649_CR177","unstructured":"MAP2K6 mitogen-activated protein kinase kinase 6 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene\/5608"},{"issue":"3","key":"10649_CR178","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/MNH.0000000000001070","volume":"34","author":"JX Huang","year":"2025","unstructured":"Huang JX, Peschard VG, Ku E. Impact of intensive blood pressure control on kidney outcomes. Curr Opin Nephrol Hypertens. 2025;34(3):224\u201331. https:\/\/doi.org\/10.1097\/MNH.0000000000001070.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10649_CR179","unstructured":"RAF1 Raf-1 proto-oncogene, serine\/threonine kinase [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved June 1, 2025, from https:\/\/www.ncbi.nlm.nih.gov\/gene\/5894"},{"issue":"6","key":"10649_CR180","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A\/ASSET\/F6F5AB6E-36BF-4939-8015-3F8C5FC1C0C6\/ASSETS\/GRAPHIC\/14FF5.JPEG","volume":"110","author":"IS Harris","year":"2004","unstructured":"Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation. 2004;110(6):718\u201323. https:\/\/doi.org\/10.1161\/01.CIR.0000138190.50127.6A\/ASSET\/F6F5AB6E-36BF-4939-8015-3F8C5FC1C0C6\/ASSETS\/GRAPHIC\/14FF5.JPEG.","journal-title":"Circulation"},{"key":"10649_CR181","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/ANNUREV-BIOENG-071114-040647\/1","volume":"19","author":"M Levin","year":"2017","unstructured":"Levin M, Pezzulo G, Finkelstein JM. Endogenous bioelectric signaling networks: exploiting voltage gradients for control of growth and form. Annu Rev Biomed Eng. 2017;19:353\u201387. https:\/\/doi.org\/10.1146\/ANNUREV-BIOENG-071114-040647\/1.","journal-title":"Annu Rev Biomed Eng"},{"key":"10649_CR182","doi-asserted-by":"publisher","unstructured":"Xu Z, Dong M, Yin S, Dong J, Zhang M, Tian R, \u2026 Chen J. Why traditional herbal medicine promotes wound healing: Research from immune response, wound microbiome to controlled delivery. Adv Drug Deliv Rev. 2023;195:114764. https:\/\/doi.org\/10.1016\/J.ADDR.2023.114764","DOI":"10.1016\/J.ADDR.2023.114764"},{"key":"10649_CR183","doi-asserted-by":"publisher","first-page":"1250073","DOI":"10.3389\/FCVM.2023.1250073\/BIBTEX","volume":"10","author":"TC Palmer","year":"2023","unstructured":"Palmer TC, Hunter RW. Using RNA-based therapies to target the kidney in cardiovascular disease. Front Cardiovasc Med. 2023;10:1250073. https:\/\/doi.org\/10.3389\/FCVM.2023.1250073\/BIBTEX.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10649_CR184","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/J.TIPS.2020.09.001\/ASSET\/83EDC1B5-6360-4E12-A190-55492A790AFA\/MAIN.ASSETS\/GR3.SML","volume":"41","author":"L He","year":"2020","unstructured":"He L. Metformin and systemic metabolism. Trends Pharmacol Sci. 2020;41(11):868\u201381. https:\/\/doi.org\/10.1016\/J.TIPS.2020.09.001\/ASSET\/83EDC1B5-6360-4E12-A190-55492A790AFA\/MAIN.ASSETS\/GR3.SML.","journal-title":"Trends Pharmacol Sci"},{"key":"10649_CR185","doi-asserted-by":"publisher","unstructured":"Piegari E, Cozzolino A, Ciuffreda LP, Cappetta D, De Angelis A, Urbanek K, \u2026 Berrino L. Cardioprotective effects of miR-34a silencing in a rat model of doxorubicin toxicity. Sci Rep. 2020;10(1):1\u201312. https:\/\/doi.org\/10.1038\/s41598-020-69038-3","DOI":"10.1038\/s41598-020-69038-3"},{"key":"10649_CR186","unstructured":"MicroRNA-146a inhibits NF-\u03baB activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells. (n.d.). Retrieved June 1, 2025, from https:\/\/www.spandidos-publications.com\/etm\/18\/4\/3078"},{"issue":"3","key":"10649_CR187","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/J.CARDIORES.2007.02.016\/2\/M_74-3-445-FIG3.GIF","volume":"74","author":"S Srivastava","year":"2007","unstructured":"Srivastava S, Chandrasekar B, Gu Y, Luo J, Hamid T, Hill BG, Prabhu SD. Downregulation of CuZn-superoxide dismutase contributes to \u03b2-adrenergic receptor-mediated oxidative stress in the heart. Cardiovasc Res. 2007;74(3):445\u201355. https:\/\/doi.org\/10.1016\/J.CARDIORES.2007.02.016\/2\/M_74-3-445-FIG3.GIF.","journal-title":"Cardiovasc Res"},{"key":"10649_CR188","doi-asserted-by":"publisher","unstructured":"Lan Y, Liu B, Yao H, Li F, Weng T, Yang G, \u2026 Yang X. Essential role of endothelial smad4 in vascular remodeling and integrity. Mol Cell Biol. 2007;27(21):7683\u20137692. https:\/\/doi.org\/10.1128\/MCB.00577-07","DOI":"10.1128\/MCB.00577-07"},{"issue":"5","key":"10649_CR189","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/S10157-023-02329-X\/METRICS","volume":"27","author":"S Saito","year":"2023","unstructured":"Saito S, Ohno SI, Harada Y, Kanno Y, Kuroda M. MiR-34a induces myofibroblast differentiation from renal fibroblasts. Clin Exp Nephrol. 2023;27(5):411\u20138. https:\/\/doi.org\/10.1007\/S10157-023-02329-X\/METRICS.","journal-title":"Clin Exp Nephrol"},{"key":"10649_CR190","doi-asserted-by":"publisher","unstructured":"Ma FY, Flanc RS, Tesch GH, Han Y, Atkins RC, Bennett BL, \u2026 Nikolic-Paterson DJ. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol. 2007;18(2):472\u2013484. https:\/\/doi.org\/10.1681\/ASN.2006060604","DOI":"10.1681\/ASN.2006060604"},{"key":"10649_CR191","doi-asserted-by":"publisher","unstructured":"Bageghni SA, Hemmings KE, Zava N, Denton CP, Porter KE, Ainscough JFX, \u2026 Turner N. A. Cardiac fibroblast-specific p38\u03b1 MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism. FASEB J. 2018;32(9):4941. https:\/\/doi.org\/10.1096\/FJ.201701455RR","DOI":"10.1096\/FJ.201701455RR"},{"issue":"3","key":"10649_CR192","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/J.SEMNEPHROL.2012.04.003","volume":"32","author":"ME Choi","year":"2012","unstructured":"Choi ME, Ding Y, Kim SI. TGF-\u03b2 signaling via TAK1 pathway: role in kidney fibrosis. Semin Nephrol. 2012;32(3):244\u201352. https:\/\/doi.org\/10.1016\/J.SEMNEPHROL.2012.04.003.","journal-title":"Semin Nephrol"},{"key":"10649_CR193","doi-asserted-by":"publisher","unstructured":"Romero-Becerra R, Mora A, Manieri E, Nikolic I, Santamans AM, Montalvo-Romeral V, \u2026 Sabio G. MKK6 deficiency promotes cardiac dysfunction through MKK3-p38\u03b3\/\u03b4-mTOR hyperactivation. eLife. 2022;11. https:\/\/doi.org\/10.7554\/ELIFE.75250","DOI":"10.7554\/ELIFE.75250"},{"key":"10649_CR194","doi-asserted-by":"publisher","unstructured":"Cuevas-Navarro A, Wagner M, Van R, Swain M, Mo S, Columbus J, \u2026 Castel P. RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy. Sci Adv. 2023;9(28). https:\/\/doi.org\/10.1126\/SCIADV.ADF4766\/SUPPL_FILE\/SCIADV.ADF4766_SM.PDF","DOI":"10.1126\/SCIADV.ADF4766\/SUPPL_FILE\/SCIADV.ADF4766_SM.PDF"},{"issue":"3","key":"10649_CR195","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1152\/AJPRENAL.00086.2009\/ASSET\/IMAGES\/LARGE\/ZH20090956360008.JPEG","volume":"297","author":"H Noh","year":"2009","unstructured":"Noh H, Eun YO, Ji YS, Mi RY, Young OK, Ha H, Hi BL. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-\u03b21-induced renal injury. Am J Physiol-Ren Physiol. 2009;297(3):729\u201339. https:\/\/doi.org\/10.1152\/AJPRENAL.00086.2009\/ASSET\/IMAGES\/LARGE\/ZH20090956360008.JPEG.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"10649_CR196","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/J.YJMCC.2020.05.007","volume":"144","author":"JM Grimes","year":"2020","unstructured":"Grimes JM, Grimes KV. p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol. 2020;144:63\u20135. https:\/\/doi.org\/10.1016\/J.YJMCC.2020.05.007.","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"10649_CR197","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/S11255-021-02836-4\/FIGURES\/6","volume":"53","author":"S Hu","year":"2021","unstructured":"Hu S, Hu H, Wang R, He H, Shui H. microRNA-29b prevents renal fibrosis by attenuating renal tubular epithelial cell\u2013mesenchymal transition through targeting the PI3K\/AKT pathway. Int Urol Nephrol. 2021;53(9):1941\u201350. https:\/\/doi.org\/10.1007\/S11255-021-02836-4\/FIGURES\/6.","journal-title":"Int Urol Nephrol"},{"key":"10649_CR198","doi-asserted-by":"publisher","unstructured":"Zhang WC, Yang JH, Liu GH, Yang F, Gong JL, Jia MG, \u2026 Zhao LS. miR-34b\/c regulates doxorubicin-induced myocardial cell injury through ITCH. Cell Cycle. 2019;18(23):3263\u20133274. https:\/\/doi.org\/10.1080\/15384101.2019.1673618;WGROUP:STRING:PUBLICATION","DOI":"10.1080\/15384101.2019.1673618;WGROUP:STRING:PUBLICATION"},{"key":"10649_CR199","doi-asserted-by":"publisher","unstructured":"Li B, Wu J, Bao J, Han X, Shen S, Ye X, \u2026 Hu G. Activation of \u03b17nACh receptor protects against acute pancreatitis through enhancing TFEB-regulated autophagy. Biochim Biophys Acta (BBA) \u2013 Mol Basis Dis. 2020;1866(12):165971. https:\/\/doi.org\/10.1016\/J.BBADIS.2020.165971","DOI":"10.1016\/J.BBADIS.2020.165971"},{"issue":"3","key":"10649_CR200","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/10600280221105169","volume":"57","author":"E Samuel","year":"2023","unstructured":"Samuel E, Watford M, Egolum UO, Ombengi DN, Ling H, Cates DW. Inclisiran: a first-in-class siRNA therapy for lowering low-density lipoprotein cholesterol. Ann Pharmacother. 2023;57(3):317\u201324. https:\/\/doi.org\/10.1177\/10600280221105169.","journal-title":"Ann Pharmacother"},{"key":"10649_CR201","doi-asserted-by":"publisher","unstructured":"Dimitriadis K, Theofilis P, Iliakis P, Pyrpyris N, Dri E, Sakalidis A, \u2026 Tsioufis K. Management of dyslipidemia in coronary artery disease: the present and the future. Coron Artery Dis. 2024;35(6):516\u2013524. https:\/\/doi.org\/10.1097\/MCA.0000000000001375","DOI":"10.1097\/MCA.0000000000001375"},{"key":"10649_CR202","doi-asserted-by":"publisher","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, \u2026 Rambaran C. Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA. 2024;332(23):1992\u20132002. https:\/\/doi.org\/10.1001\/JAMA.2024.21957","DOI":"10.1001\/JAMA.2024.21957"},{"key":"10649_CR203","doi-asserted-by":"publisher","unstructured":"Vasas S, Azizad M, Clifton P, Rosenson R, Gaudet D, Hellawell J, \u2026 Ballantyne C. Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results. J Clin Lipidol. 2024;18(4):e560. https:\/\/doi.org\/10.1016\/J.JACL.2024.04.098","DOI":"10.1016\/J.JACL.2024.04.098"},{"issue":"4","key":"10649_CR204","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.tcm.2023.01.008","volume":"34","author":"F Luo","year":"2024","unstructured":"Luo F, Das A, Khetarpal SA, Fang Z, Zelniker TA, Rosenson RS, Qamar A. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends Cardiovasc Med. 2024;34(4):215\u201322. https:\/\/doi.org\/10.1016\/j.tcm.2023.01.008.","journal-title":"Trends Cardiovasc Med"},{"key":"10649_CR205","doi-asserted-by":"publisher","unstructured":"Thielmann M, Corteville D, Szabo G, Swaminathan M, Lamy A, Lehner LJ, \u2026 Mazer CD. Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation. 2021;144(14):1133\u20131144. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.053029\/SUPPL_FILE\/CIRC_CIRCULATIONAHA-2020-053029_SUPP1.PDF","DOI":"10.1161\/CIRCULATIONAHA.120.053029\/SUPPL_FILE\/CIRC_CIRCULATIONAHA-2020-053029_SUPP1.PDF"},{"issue":"23","key":"10649_CR206","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/EURHEARTJ\/EHV010","volume":"36","author":"K Damman","year":"2015","unstructured":"Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36(23):1437\u201344. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHV010.","journal-title":"Eur Heart J"},{"key":"10649_CR207","doi-asserted-by":"publisher","unstructured":"Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Computational\/in silico methods in drug target and lead prediction. Brief Bioinform. n.d.;21(5):1663\u20131675. https:\/\/doi.org\/10.1093\/bib\/bbz103","DOI":"10.1093\/bib\/bbz103"},{"key":"10649_CR208","doi-asserted-by":"publisher","unstructured":"Savoji H, Mohammadi MH, Rafatian N, Toroghi MK, Wang EY, Zhao Y, \u2026 Radisic M. Cardiovascular disease models: a game changing paradigm in drug discovery and screening. Biomaterials. 2019;198:3\u201326. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2018.09.036","DOI":"10.1016\/J.BIOMATERIALS.2018.09.036"},{"key":"10649_CR209","doi-asserted-by":"publisher","unstructured":"Tanase DM, Valasciuc E, Anton IB, Gosav EM, Dima N, Cucu AI, \u2026 Floria M. Matrix metalloproteinases: pathophysiologic implications and potential therapeutic targets in cardiovascular disease. Biomolecules. 2025;15(4):598. https:\/\/doi.org\/10.3390\/BIOM15040598","DOI":"10.3390\/BIOM15040598"},{"key":"10649_CR210","doi-asserted-by":"publisher","unstructured":"Hueso M, Casas A, Mall\u00e9n A, De Ram\u00f3n L, Bola\u00f1os N, Varela C, \u2026 Navarro E. The double edge of anti-CD40 siRNA therapy: It increases renal microcapillar density but favours the generation of an inflammatory milieu in the kidneys of ApoE -\/- mice. J Inflamm (United Kingdom). 2019;16(1):1\u20139. https:\/\/doi.org\/10.1186\/S12950-019-0228-9\/FIGURES\/3","DOI":"10.1186\/S12950-019-0228-9\/FIGURES\/3"},{"key":"10649_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2024.176467","volume":"969","author":"S Tanna","year":"2024","unstructured":"Tanna S, Doshi G, Godad A. siRNA as potential therapeutic strategy for hypertension. Eur J Pharmacol. 2024;969: 176467. https:\/\/doi.org\/10.1016\/J.EJPHAR.2024.176467.","journal-title":"Eur J Pharmacol"},{"key":"10649_CR212","doi-asserted-by":"publisher","unstructured":"Tang W, Panja S, Jogdeo CM, Tang S, Ding L, Yu A, \u2026 Oupick\u00fd D. Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury. Biomaterials. 2022;285:121562. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2022.121562","DOI":"10.1016\/J.BIOMATERIALS.2022.121562"},{"key":"10649_CR213","doi-asserted-by":"publisher","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang C-C, Ueda M, Kristen AV, \u2026 Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMOA1716153\/SUPPL_FILE\/NEJMOA1716153_DISCLOSURES.PDF","DOI":"10.1056\/NEJMOA1716153\/SUPPL_FILE\/NEJMOA1716153_DISCLOSURES.PDF"},{"key":"10649_CR214","doi-asserted-by":"publisher","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, \u2026 Kastelein JJP. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u20131530. https:\/\/doi.org\/10.1056\/NEJMOA1913805\/SUPPL_FILE\/NEJMOA1913805_DATA-SHARING.PDF","DOI":"10.1056\/NEJMOA1913805\/SUPPL_FILE\/NEJMOA1913805_DATA-SHARING.PDF"},{"key":"10649_CR215","doi-asserted-by":"publisher","unstructured":"Lin H, Geurts F, Hassler L, Batlle D, Colafella KMM, Denton KM, \u2026 Danser AHJ. Kidney angiotensin in cardiovascular disease: formation and drug targeting. Pharmacol Rev. 2022;74(3):462\u2013505. https:\/\/doi.org\/10.1124\/PHARMREV.120.000236","DOI":"10.1124\/PHARMREV.120.000236"},{"issue":"21","key":"10649_CR216","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.3390\/JCM13216311","volume":"13","author":"U Schuth","year":"2024","unstructured":"Schuth U, Gill K, Telyuk P, Bawamia BR, Austin D, Zaman A. Role of lipoprotein(a) reduction in cardiovascular disease. J Clin Med. 2024;13(21):6311. https:\/\/doi.org\/10.3390\/JCM13216311.","journal-title":"J Clin Med"},{"key":"10649_CR217","doi-asserted-by":"publisher","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, \u2026 Kastelein JJP. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u20131519. https:\/\/doi.org\/10.1056\/NEJMOA1912387\/SUPPL_FILE\/NEJMOA1912387_DATA-SHARING.PDF","DOI":"10.1056\/NEJMOA1912387\/SUPPL_FILE\/NEJMOA1912387_DATA-SHARING.PDF"},{"issue":"2","key":"10649_CR218","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/J.YMTHE.2024.01.005\/ASSET\/6C651F44-3058-43A7-A20F-4285E0C56F06\/MAIN.ASSETS\/GR3.JPG","volume":"32","author":"M Moazzam","year":"2024","unstructured":"Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther. 2024;32(2):284\u2013312. https:\/\/doi.org\/10.1016\/J.YMTHE.2024.01.005\/ASSET\/6C651F44-3058-43A7-A20F-4285E0C56F06\/MAIN.ASSETS\/GR3.JPG.","journal-title":"Mol Ther"},{"key":"10649_CR219","doi-asserted-by":"publisher","unstructured":"Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peir\u00f3 P, Montgomery Bissell D, Stein PE, \u2026 Sardh E. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2022;42(1):161\u2013172. https:\/\/doi.org\/10.1111\/LIV.15090;SUBPAGE:STRING:FULL","DOI":"10.1111\/LIV.15090;SUBPAGE:STRING:FULL"},{"key":"10649_CR220","doi-asserted-by":"publisher","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, \u2026 Witztum JL. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u2013255. https:\/\/doi.org\/10.1056\/NEJMOA1905239\/SUPPL_FILE\/NEJMOA1905239_DATA-SHARING.PDF","DOI":"10.1056\/NEJMOA1905239\/SUPPL_FILE\/NEJMOA1905239_DATA-SHARING.PDF"},{"key":"10649_CR221","doi-asserted-by":"publisher","unstructured":"Ray KK, Ruotolo G, Michael L, Shen X, Ma X, Lim S, \u2026 Linnebjerg H. Solbinsiran, a galnac-conjugated sirna targeting angptl3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dosedependent manner. J Am Coll Cardiol. 2024;83(13):1673. https:\/\/doi.org\/10.1016\/S0735-1097(24)03663-5","DOI":"10.1016\/S0735-1097(24)03663-5"},{"key":"10649_CR222","doi-asserted-by":"publisher","unstructured":"Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, \u2026 Burris HA. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406\u2013417. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0429\/42290\/AM\/FIRST-IN-MAN-TRIAL-OF-AN-RNA-INTERFERENCE","DOI":"10.1158\/2159-8290.CD-12-0429\/42290\/AM\/FIRST-IN-MAN-TRIAL-OF-AN-RNA-INTERFERENCE"},{"key":"10649_CR223","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.omtn.2023.03.020","volume":"32","author":"B Hu","year":"2023","unstructured":"Hu B, Huang Y. siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy. Mol Ther Nucleic Acids. 2023;32:369\u201370. https:\/\/doi.org\/10.1016\/j.omtn.2023.03.020.","journal-title":"Mol Ther Nucleic Acids"},{"key":"10649_CR224","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000645","author":"RS Khan","year":"2024","unstructured":"Khan RS, Frishman WH. Zilebesiran: a promising antihypertensive therapy inhibiting angiotensinogen synthesis. Cardiol Rev. 2024. https:\/\/doi.org\/10.1097\/CRD.0000000000000645.","journal-title":"Cardiol Rev"},{"key":"10649_CR225","doi-asserted-by":"publisher","unstructured":"Li SH, Lu HI, Chang AYW, Huang WT, Lin WC, Lee CC, \u2026 Chen CH. Angiotensin II type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation. Oncotarget. 2016;7(41):67150. https:\/\/doi.org\/10.18632\/ONCOTARGET.11567","DOI":"10.18632\/ONCOTARGET.11567"},{"key":"10649_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2023.115073","volume":"201","author":"J Won Lee","year":"2023","unstructured":"Won Lee J, Kyu Shim M, Kim H, Jang H, Lee Y, Hwa Kim S. RNAi therapies: expanding applications for extrahepatic diseases and overcoming delivery challenges. Adv Drug Deliv Rev. 2023;201: 115073. https:\/\/doi.org\/10.1016\/J.ADDR.2023.115073.","journal-title":"Adv Drug Deliv Rev"},{"key":"10649_CR227","doi-asserted-by":"publisher","unstructured":"Bov\u00e9e DM, Ren L, Uijl E, Clahsen-Van Groningen MC, Van Veghel R, Garrelds IM, \u2026 Jan Danser AH. Renoprotective effects of small interfering RNA targeting liver angiotensinogen in experimental chronic kidney disease. Hypertension. 2021;77(5):1600\u20131612. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16876\/SUPPL_FILE\/HYP_HYPE-2020-16876_SUPP4.PDF","DOI":"10.1161\/HYPERTENSIONAHA.120.16876\/SUPPL_FILE\/HYP_HYPE-2020-16876_SUPP4.PDF"},{"key":"10649_CR228","doi-asserted-by":"publisher","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, \u2026 Ballantyne CM. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u2013630. https:\/\/doi.org\/10.1001\/JAMACARDIO.2024.0959","DOI":"10.1001\/JAMACARDIO.2024.0959"},{"key":"10649_CR229","doi-asserted-by":"publisher","unstructured":"Saddique MN, Qadri M, Ain NU, Farhan E, Shahid F, Benyamin J, \u2026 Iqbal J. Safety and effectiveness of interference RNA (RNAi) based therapeutics in cardiac failure: a systematic review. Heart Lung. 2024;68:298\u2013304. https:\/\/doi.org\/10.1016\/J.HRTLNG.2024.08.015","DOI":"10.1016\/J.HRTLNG.2024.08.015"},{"key":"10649_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107102","volume":"201","author":"MD P\u00e9rez-Carri\u00f3n","year":"2024","unstructured":"P\u00e9rez-Carri\u00f3n MD, Posadas I, Ce\u00f1a V. Nanoparticles and siRNA: a new era in therapeutics? Pharmacol Res. 2024;201: 107102. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107102.","journal-title":"Pharmacol Res"},{"issue":"3","key":"10649_CR231","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/NAT.2018.0736\/ASSET\/IMAGES\/LARGE\/FIGURE1.JPEG","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109\u201318. https:\/\/doi.org\/10.1089\/NAT.2018.0736\/ASSET\/IMAGES\/LARGE\/FIGURE1.JPEG.","journal-title":"Nucleic Acid Ther"},{"issue":"5","key":"10649_CR232","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/PHARMACEUTICS17050555","volume":"17","author":"AK Srivastav","year":"2025","unstructured":"Srivastav AK, Mishra MK, Lillard JW, Singh R. Transforming pharmacogenomics and CRISPR gene editing with the power of artificial intelligence for precision medicine. Pharmaceutics. 2025;17(5):555. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17050555.","journal-title":"Pharmaceutics"},{"issue":"1","key":"10649_CR233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12864-023-09227-2\/TABLES\/3","volume":"24","author":"M Wang","year":"2023","unstructured":"Wang M, Wu J, Lei S, Mo X. Genome-wide identification of RNA modification-related single nucleotide polymorphisms associated with rheumatoid arthritis. BMC Genomics. 2023;24(1):1\u201315. https:\/\/doi.org\/10.1186\/S12864-023-09227-2\/TABLES\/3.","journal-title":"BMC Genomics"},{"issue":"22","key":"10649_CR234","doi-asserted-by":"publisher","first-page":"13725","DOI":"10.3390\/IJMS232213725","volume":"23","author":"E Rykova","year":"2022","unstructured":"Rykova E, Ershov N, Damarov I, Merkulova T. SNPs in 3\u2032UTR miRNA target sequences associated with individual drug susceptibility. Int J Mol Sci. 2022;23(22):13725. https:\/\/doi.org\/10.3390\/IJMS232213725.","journal-title":"Int J Mol Sci"},{"key":"10649_CR235","doi-asserted-by":"publisher","unstructured":"Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, Wong GKS. Recent update on siRNA therapeutics. Int J Mol Sci. 2025;26(8). https:\/\/doi.org\/10.3390\/IJMS26083456","DOI":"10.3390\/IJMS26083456"},{"issue":"18","key":"10649_CR236","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1021\/ACS.JMEDCHEM.4C01330","volume":"67","author":"S Chen","year":"2024","unstructured":"Chen S, Mao Q, Cheng H, Tai W. RNA-binding small molecules in drug discovery and delivery: an overview from fundamentals. J Med Chem. 2024;67(18):16002\u201317. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.4C01330.","journal-title":"J Med Chem"},{"issue":"5","key":"10649_CR237","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/J.AJPS.2018.12.005","volume":"14","author":"MAG Raja","year":"2019","unstructured":"Raja MAG, Katas H, Amjad MW. Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA. Asian J Pharm Sci. 2019;14(5):497\u2013510. https:\/\/doi.org\/10.1016\/J.AJPS.2018.12.005.","journal-title":"Asian J Pharm Sci"},{"issue":"3","key":"10649_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTN.2024.102313\/ASSET\/78B1EE74-E85D-477F-B3C4-52F9384DE929\/MAIN.ASSETS\/GR4.JPG","volume":"35","author":"Z Eftekhari","year":"2024","unstructured":"Eftekhari Z, Zohrabi H, Oghalaie A, Ebrahimi T, Shariati FS, Behdani M, Kazemi-Lomedasht F. Advancements and challenges in mRNA and ribonucleoprotein-based therapies: from delivery systems to clinical applications. Mol Ther-Nucleic Acids. 2024;35(3): 102313. https:\/\/doi.org\/10.1016\/J.OMTN.2024.102313\/ASSET\/78B1EE74-E85D-477F-B3C4-52F9384DE929\/MAIN.ASSETS\/GR4.JPG.","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"4","key":"10649_CR239","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/BIOMEDICINES13040790","volume":"13","author":"F Schinzari","year":"2025","unstructured":"Schinzari F, Montenero R, Cardillo C, Tesauro M. Emerging pharmacological approaches for the treatment of arterial hypertension. Biomedicines. 2025;13(4):790. https:\/\/doi.org\/10.3390\/BIOMEDICINES13040790.","journal-title":"Biomedicines"},{"key":"10649_CR240","doi-asserted-by":"publisher","unstructured":"Xu W, Jiang X, Huang L. RNA interference technology. Compr Biotechnol. 2019;560. https:\/\/doi.org\/10.1016\/B978-0-444-64046-8.00282-2","DOI":"10.1016\/B978-0-444-64046-8.00282-2"},{"key":"10649_CR241","doi-asserted-by":"publisher","unstructured":"Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, \u2026 Crooke ST. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol. 2019;37(6):640\u2013650. https:\/\/doi.org\/10.1038\/S41587-019-0106-2;SUBJMETA=154,1914,391,570,61,631;KWRD=ANTISENSE+OLIGONUCLEOTIDE+THERAPY,TOXICOLOGY","DOI":"10.1038\/S41587-019-0106-2;SUBJMETA=154,1914,391,570,61,631;KWRD=ANTISENSE+OLIGONUCLEOTIDE+THERAPY,TOXICOLOGY"},{"issue":"2","key":"10649_CR242","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/J.YMTHE.2020.11.008\/ASSET\/8A0121B2-2A10-4D3E-9415-1BFE320ABB18\/MAIN.ASSETS\/GR1.JPG","volume":"29","author":"M Herkt","year":"2021","unstructured":"Herkt M, Thum T. Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics. Mol Ther. 2021;29(2):521\u201339. https:\/\/doi.org\/10.1016\/J.YMTHE.2020.11.008\/ASSET\/8A0121B2-2A10-4D3E-9415-1BFE320ABB18\/MAIN.ASSETS\/GR1.JPG.","journal-title":"Mol Ther"},{"issue":"9","key":"10649_CR243","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCULATIONAHA.123.067373\/ASSET\/C02BD51C-BC2D-40F2-B981-CF41F08C5259\/ASSETS\/GRAPHIC\/CIRCULATIONAHA.123.067373.FIG02.JPG","volume":"149","author":"VJ Dzau","year":"2024","unstructured":"Dzau VJ, Hodgkinson CP. RNA therapeutics for the cardiovascular system. Circulation. 2024;149(9):707\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067373\/ASSET\/C02BD51C-BC2D-40F2-B981-CF41F08C5259\/ASSETS\/GRAPHIC\/CIRCULATIONAHA.123.067373.FIG02.JPG.","journal-title":"Circulation"},{"issue":"4","key":"10649_CR244","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/S12276-022-00757-5","volume":"54","author":"YK Kim","year":"2022","unstructured":"Kim YK. RNA therapy: rich history, various applications and unlimited future prospects. Exp Mol Med. 2022;54(4):455\u201365. https:\/\/doi.org\/10.1038\/S12276-022-00757-5.","journal-title":"Exp Mol Med"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10649-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10649-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10649-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:19:34Z","timestamp":1765549174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10649-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":244,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10649"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10649-4","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent for Publication"}},{"value":"The authors declare that there are no conflicts of interest related to this research.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The authors affirm that there are no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}